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Abstract 
	  
While acute inflammation is important in immune responses to infection, chronic 
systemic inflammation intrinsically underlies age-associated pathologies. Lifelong 
cellular turnover equates biological age with long term accumulation of senescent cells, 
characterized by cell-cycle arrest and a pro-inflammatory senescence-associated secretory 
phenotype (SASP). Currently, the exact contributions of lymphocytes to the inflammatory 
landscape seen during aging remains understudied.	   Cytomegalovirus (CMV) infection 
creates an inflated, potentially senescent, CD8+ T lymphocyte population, often 
exaggerated in age and in particular, human immunodeficiency virus (HIV) infection. 
Many living with long-term HIV infection often suffer “premature” age-related illnesses. 
Frequent rounds of antigen-driven expansion of CMV-specific lymphocytes could 
introduce a telomere-dependent SASP and a role in suspected age-related pathology.	  
Using a 4-parameter flowFISH assay to quantify telomere length in peripheral blood 
lymphocytes, we show	   in HIV-infected CMV-seropositive individuals (n=32) that 
CD57+CD8+ T cells responding to CMV had the shortest telomere lengths compared to 
CD57+CD8+, global CD8+ and CD8+ T cells responding to HIV (p < 0.001, 0.001, 0.04, 
respectively). CMV-seropositive HIV-infected study groups (n=97) show higher 
circulating pro-inflammatory cytokine levels than those not infected with CMV (n=19), 
further linking CMV immunity, immune senescence and inflammation.	  Our data support 
consideration that CMV infection associated expansion of CD8+ T cells compound the 
effects of natural aging on chronic inflammation.   
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1 Introduction 
1.1 Biological Aging 
Aging, broadly stated, is the long-term decline in physiological function 
occurring in a time-dependent manner. The biological process of aging is often thought of 
as an “accumulation of changes,” however, the exact nature of these changes is widely 
disputed and often far more interconnected than appreciated. This age-associated 
accumulation is conceptualized as biological entropy, where damaged, less functional 
cells gradually collect in each tissue.  This culminates through late ages as organ disease 
or dysfunction, effectively manifesting as a decline in physiological function. It is of great 
interest to define and discriminate the changes accumulated during aging to understand 
how these features could become accelerated or initiated prematurely, thereby promoting 
early morbidity and mortality. From a biological perspective, to understand the advancing 
detriment of aging on the human population, the compositional changes of the body 
during aging must first be better understood by more precisely identifying the key 
molecular and cellular “changes” that “accumulate.”  
1.1.1 Cellular Senescence 
To senesce, from Latin senescere, is defined as “to grow old”. Senescing, or 
becoming senescent, is the biological term originating from Hayflick et al. to describe the 
loss of replicative capacity, or replicative senescence, first observed in in vitro fibroblast 
cultures. This observation, however, addressed only one extrinsic aspect of “senescence” 
and merely fueled speculation of an internal process or underlying mechanism that 
inhibits cell replication, somehow, dependent on the length of time in culture1. To show 
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that this progressive decline in replication was not only restricted to cell lines in vitro, but 
reflected an in vivo process, Harley et al. demonstrated that cultured primary human 
fibroblasts showed the same decline in replication capacity over time and that this was 
physically reflected in fibroblast telomere length2. Furthermore, the duration of fibroblast 
replication in vitro and telomere length were both directly related to the age of the donor.  
Functionally, telomere sequences are noncoding and essentially serve as a protective cap 
to linear chromosomes, which encode all function and if damaged could incorporate 
harmful mutations and/or trigger cell death. This in vivo connection to ageing positioned 
telomere length as a surrogate cellular indicator of age, or ‘biological clock.’ The 
telomere is a hexameric repeat of TTAGGG with sequence length ranging from 18 
kilobase pairs in cellular infancy to a few thousand-base pairs in old cells3,4. The position 
of the telomere is both incredibly strategic to stabilize chromosomal DNA and the 
“Achilles heel” of long-term stability of chromosomal DNA with cumulative replication.  
Most DNA polymerases utilized during cell division operate in a unidirectional 5`-3` 
direction and can only bind to existing primer regions, creating problems for the Okazaki 
fragments of the lagging strands (3`-5`) where RNA primers are required. Since there is 
no site for attachment preceding the most 5’ RNA primer, when RNA primers are 
degraded post-DNA replication, a resultant 3’ overhang of approximately 25 base pairs 
remains exposed and eventually is degraded. This telomere eroding process, termed the 
end-replication problem, occurs with every cell division5. While the chromosomal coding 
DNA is protected, it is at the expense of telomere length. An RNA-dependent DNA 
polymerase, telomerase, can restore sections of the TTAGGG sequence during DNA 
replication, effectively eliminating the end replication problem. While this is employed 
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by embryonic cells during intermittent cell division6, telomerase is generally absent in 
differentiated cells in vivo7, where the end-replication issue drives telomere erosion. 
Therefore, the absolute length of the telomere reflects both the history of -and the 
potential for further- cellular replication in somatic tissue.  
Cell cycle arrest is often initiated as an anti-tumorigenic response to internal 
stresses, generally due to the detection of aberrations in nuclear or mitochondrial DNA. 
Momentary cell cycle arrest allows evaluation of said internal damage, its potential repair 
and eventual cell cycle progression. If internal cues for cell cycle arrest are interpreted as 
high risk for neoplastic transformation or oncogenesis, the cell becomes apoptotic or 
maintains cell-cycle arrest, acquiring a senescent phenotype.  Cellular senescence is 
classically defined by terminal cycle arrest, resistance to apoptosis, and altered cellular 
function. A deeper understanding of cellular senescence now defines it as much more 
than the traditional tumor suppressor state8. In fact, cellular senescence is a dynamic 
process not only integral to cellular and tissue aging but unbeknownst to Hayflick et al, 
heavily involved in tissue and vascular homeostasis. Senescent cellular differentiation 
spans all cell types and tissue microenvironments, each cell encountering different 
extracellular cues and each with its own senescence-associated alterations in function, and 
therefore, differential contributions to organismal aging. Given the many instances of 
internal damages and stress our cells undergo throughout our lifetime, a better 
understanding of the complexity and pleiotropy of senescent processes could not only 
shed light on endogenous mechanisms of aging, but also on key homeostatic mechanisms 
such as cancer prevention and wound healing.  
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1.1.2 Senescent Cell Programing 
Senescence can be viewed as a programmed response to stressful events that 
follows distinct acute and chronic scenarios. Much like the immune response to acute 
viral infections, acute senescence is rapid and well-orchestrated, ultimately including 
immune-mediated cell clearance. Chronic senescence, like the immune response to 
chronic infection, is the decelerated, deleterious, more detrimentally progressive state 
commonly associated with age-related diseases9.  
Acute cellular senescence contributes to tissue repair10 and is integral to 
processes such as embryogenesis and maternal vascular remodeling11,12. The key feature 
of acute senescence is the rapidity of onset and subsequent clearance of senescent cells by 
the immune system. Acute senescent cells receive short high-grade extracellular damage 
signals, which trigger accumulation of stress signaling molecules that impose cell cycle 
arrest. Acute senescence rapidly invokes a distinct phenotypic change that empowers 
selective elimination of the senescent cells by the immune system. Acute senescent events 
terminate with cell clearance to maintain proper tissue function9. The absence of 
orchestrated cell clearance and subsequent senescent cell accumulation forms the 
canonical connection between chronic cell senescence and unhealthy aging.  
As first demonstrated by Hayflick et al., long-term passage of fibroblasts 
eventually results in cell cycle arrest, reflected in chronic cellular senescence. Induction 
of senescence occurs via successive DNA damage responses due to critically shortened 
telomeres13. Due to the end replication problem, exhaustively proliferated cells have 
telomeres shortened to dangerous lengths that results in them becoming ‘uncapped.’ 
These exposed telomeres mimic double-strand DNA breaks (DSB) and trigger DNA 
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damage response (DDR) pathways involving the master regulator protein p5314. Cell 
cycle arrest is initiated through p53-dependent gene expression patterns resulting in 
expression of cyclin dependent kinase inhibitors p16 and p21 that impose irreversible cell 
cycle arrest. With cell cycle arrest, chromatin remodeling and genomic structural decline 
alter gene accessibility and expression15–17. Therefore, normal cellular processes suffer, 
often becoming aberrant or dysfunctional, and the chronic senescent cell develops a 
unique phenotype based on its cell type and previous functions. It is critical to identify 
how chronic senescent cell accumulation alters specific and general tissue 
microenvironments in vivo. 
Processes such as telomere erosion create progressive endogenous 
microaggressions that persistently stress cells. This type of chronic, long-term cumulative 
stress on homeostatic cell function does not overwhelm the cell into acute senescence, but 
eventually culminates in chronic senescence. Chronic endogenous triggers have been 
mimicked using low dose irradiation to create genotoxic DSBs and chromosomal 
aberrations that generate similar senescence responses to those seen in previous in vitro 
studies. Irradiated young healthy mice respond with stable increases in tissue expression 
of the cell-cycle arrest marker, p16. The resulting increase in cell cycle arrest was 
accompanied by decreases in chromatin remodeling localized to tissue areas 
demonstrating extensive damage to the extracellular matrix14.  
Transcriptional analyses of telomere eroded cultures, irradiated cultures,  and 
isolated murine p16+ tissue-resident cells all indicate significant up-regulation of 
pathways triggering expression of active soluble factors such as interleukins, chemokines, 
growth factors, and proteases18–21.  The prominent increase in production of these 
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mediators exhibited during cell-cycle arrest led to adoption of the term “senescence-
associated secretory phenotype” or SASP to describe features associated with chronic cell 
senescence8. This senescence-initiated reprogramming positions chronic senescent cells 
as major sources of inflammatory and other soluble factors that potentially alter 
microenvironments, and contribute to age-related deleterious effects on tissues. 
1.1.3 Chronic Inflammation and Aging 
Triggering acute inflammation is an important mechanism through which 
damaged or infected cells of peripheral tissues communicate with the immune system. 
Cytokines, chemokines and other small signaling molecules are secreted upon insult to 
initiate vasodilation and thus, increased tissue accessibility for immune cells. However, 
this acute immune response is a highly regulated and beneficial process. Chronic 
inflammation involves a similar process, but in contrast, becomes persistent through 
failure to eliminate the triggering insult -or is a product of autoimmunity.  Chronic sterile 
inflammation, such as results from autoimmunity, has recently been linked to the SASP 
acquired by senescent cells22.  
Chronic inflammation, distinct from the resolving inflammation generally seen 
during acute infection and insult, is the most commonly identified risk factor for mortality 
and morbidity in the elderly23. Chronic inflammation accompanies such age-related 
disorders as Alzheimer’s disease, atherosclerosis, diabetes, osteoporosis, cardiovascular 
disease and cancer16,24–29. Age-related diseases are not only exacerbated by these 
inflammatory components, but may actually require them for their development, implying 
a causal relationship between inflammation and unhealthy aging termed 
“inflammaging”30. 
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1.1.4 Soluble Mediators of “Inflammaging”  
Longitudinal human cohort studies of inflammaging have identified striking 
changes in the levels of proteins involved in immune cell activation, recruitment and 
differentiation as part of various age-associated changes in plasma composition. Modest 
increases in pro-inflammatory cytokines like tumor necrosis factor (TNF)-α, interleukin 
(IL)-6, and IL-1β, consistently occur with age9,15,31. These inflammaging components are 
produced mostly by endothelial cells that have either undergone damage, or have 
potentially become senescent, and are now attempting to communicate distress for 
clearance by immune cells. Acute senescence requires successful and immediate immune-
mediated clearance and does so via chemokine/cytokine secretion or acute inflammation. 
In contrast, the chronic systemic pro-inflammation, seen during aging, reinforces a strong 
pleiotropic, and potentially deleterious, effect on immune cells by becoming a persistent 
immune stimulus. Interestingly, the role of anti-inflammatory cytokines has not yet been 
explored in the context of unhealthy age-promotion, however, conflicting evidence in 
such age-associated alterations in cytokines, such as IL-10, suggest that it requires further 
conclusive investigation32–34. This represents a much deeper relationship between chronic 
senescence and the immune system, indicating a role for the immune system in tissue 
decline. 
In studies of parabiosis in murine models, aged mice appear to be rejuvenated by 
sharing the circulatory system of a much younger mouse. Blood components from the 
younger mouse reversed age-associated arterial thickening, prevented muscular 
degeneration and decreased the amount of DNA damage exhibited within muscle tissue 
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cells. Furthermore, these studies discriminate conserved “pro-geronic” factors between 
the donors, it was demonstrated that plasma transfusion alone had the same effect, 
confirming a role for soluble factors35,36. Key features of young plasma were low levels of 
pro-inflammatory molecules such as IL-1β, IL-6, and TNF-α34,35. These pleiotropic 
cytokines play a major role in immune cell signaling, including both activation and 
inhibition of immune cell functions. 
1.1.5 Inflammatory Paracrine Senescence 
Senescence can also be invoked through an alternate route dependent on 
proximity to chronic senescent cells. Co-culturing low passage fibroblasts with those 
exhibiting signs of senescence enforces a premature senescent phenotype and 
transcriptional pattern on the “younger” cells. The same results occurred when low-
passage fibroblasts were cultured with supernatants from senescent cells, illustrating in 
this system that soluble factors secreted from senescent cells can effectively serve as 
promoters of senescence37. It is important to note that this paracrine-mediated senescence 
has not been distinguished as a representative feature of either acute or chronic 
senescence and may effectively contribute to both. Inflammation mediated by IL-1 family 
cytokines has been identified as integral to triggering and reinforcing paracrine 
senescence38. It has been recently identified that cells reaching senescence due to 
persistant DNA damage sensing, affect growth, transcriptional profiles, and cytokine 
production in nearby cells, effectively describing an act of paracrine senescence39. It is 
reasonable to suggest, although not reported in these studies, that the younger 
counterparts in the previously described parabiosis studies suffered premature 
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accumulation of senescent cells due to the influx of inflammatory mediators, and that this 
accelerated their aging.  
Environmental stresses, such as paracrine stimulation, are now incorporated into 
the complex web of factors triggering acute and chronic senescence, thereby increasing 
the diversity of senescent phenotypes exhibited. These phenotypes depend not only on 
how senescence programming was initiated, but also on the cell type in question. The 
potential for SASPs to contribute towards the overall inflammaging environment and the 
influence of these feedback loops in instituting paracrine senescence are high priority 
subjects for studies on healthy aging. It should be noted that these inflammatory 
secretions are a form of distress signaling to immune cells to aid in senescent cell 
clearance. This increase in inflammaging is a direct product of senescent tissue 
accumulation that occurs with age, however, it also signifies the decline of immune 
mediated pro-inflammatory cell clearance. While the exact mechanism of age-related 
decline in senescent cell clearance is unknown, the senescence of immune cells 
themselves may be a critical benchmark in organismal aging. 
 1.2  T cell Immunity 
In order to identify how an immune cell, particularly those of the adaptive T cell 
lineage, can undergo senescence, we will first describe how T cells arise in vivo and 
outline a unique biology that places these immune cells at risk for telomere-dependent 
chronic senescence. 
1.2.1 Thymic Education 
Large-scale expansion of adaptive immune cells occurs during almost every 
stage of their development. Thymocyte progenitors emerge in the bone marrow and 
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migrate to the thymus for further development. Upon entering the thymus, these 
progenitor cells do not express an antigen-specific T cell receptor (TCR) or either co-
receptor, cluster of differentiation (CD) 4 or CD8. In the thymus, through a process 
known as thymic selection, these receptors are generated and ultimately represent the fate 
of the thymocytes bearing them. For simplicity, only TCR αβ−expressing T cells will be 
discussed in this thesis. The thymocyte systematically rearranges genes responsible for 
the clonotypic αβ−TCR, one at a time. Beginning rearrangement with the locus 
responsible for the β−chain, thymocytes undergo intense proliferation following a 
successful rearrangement, then proceed to TCR α−chain rearrangement, with 
proliferation ceasing once the successful αβ heterodimer is expressed. Thymocytes at this 
stage express both CD4 and CD8 and undergo successive positive and negative selection, 
to generate a final repertoire of T cells that can both sensitively and discriminately 
identify self-peptides in the context of self-human leukocyte antigen (HLA) molecules 
within an appropriate avidity threshold. As few as 2% of thymocytes survive this 
stringent thymic education, however, in each stage, high levels of proliferation occur to 
ensure sufficient numbers for the next round of selection40. IL-7, and other growth factors 
secreted by thymic stromal cells promote proliferation and survival of thymocytes, much 
like the stromal cells of the bone marrow niche41,42. Telomerase expression is directly 
enhanced by IL-7:IL-7R engagement to ensure these high levels of proliferation do not 
drive premature telomere erosion43,44. Only after surviving highly stringent selection 
processes do immature thymocytes develop into mature, yet antigen naïve, T cells and 
enter the periphery.  
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1.2.2 Peripheral T cells: Naïve, Effector and Memory 
In the periphery, naïve T cells constantly traffic throughout the blood and lymph 
system in search of cognate antigen. The naïve T cell expresses a wide variety of 
chemokine and adhesion molecule receptors that control homing and extravasation into 
lymph organs. In the secondary lymph organs, antigen-presenting cells (APC) engage T 
cells by expressing major histocompatibility complexes (MHC, or HLA in humans) 
loaded with either self-peptides, or non-self-peptides that initiate T cell activation.  
The signals needed for primary CD8+ T cell activation are generated from the 
TCR:MHC class I complex and costimulatory CD28:CD80/86 interaction. The TCR 
complex is comprised of α:β chains and clustered CD3 proteins that possess intracellular 
immunoreceptor tyrosine-based activation motifs (ITAMs) capable of initiating signalling 
cascades. Activated signalling proteins phosphorylate intracellular domains of proximal 
CD28 molecules, which generates signals resulting in nuclear factor - kappa beta (NF-
κb), mammalian target of rapamycin (mTOR), and phosphoinositol-3-kinase (PI3K) 
pathway activation. Once initiated, these activation cascades prepare the transitioning T 
cell for differentiation to an effector phenotype. NF-κB translocation is essential to 
multiple T cell responses including effector cytokine production and memory 
formation45,46. mTOR activation results in production of B-cell lymphoma (BCL) family 
proteins that inhibit apoptosis and support T cell memory formation47. PI3K cascades 
control IL-2 production and secretion. Autocrine or paracrine engagement with IL-2R 
initiates telomerase expression and subsequent proliferation of activated T cells48,49.  
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Activated T cells, as they proliferate, differentiate into effector CD8+ T cells 
possessing cytotoxic effector functions. Effector CD8+ T cells survey peripheral tissue to 
identify host cells that express cognate peptides. These peptides could be mutated self-
proteins, indicative of cancer, or could be viral proteins, reflecting viral entry into and 
replication within the host cell. Once these cells have been identified, effector functions 
are triggered and target cells are selectively killed and removed. These effector functions 
utilize proteins such as cytotoxic granzymes and perforin to create pores in the 
extracellular membrane of target cells inducing apoptosis; antiviral cytokines, interferon 
(IFN)-γ and TNF-α to activate host cells and other immune cells; cell death receptors 
Fas/FasL to trigger pro-apoptotic caspase pathways50.  
Post-pathogen clearance results in contraction of the high numbers of effector T 
cells generated by antigenic exposure, a critical phase for protection against 
immunopathology. Regulatory contraction mechanisms depend on antigen withdrawal, 
falling cytokine and chemokine levels (in particular, IL-2 or other γ chain cytokines), and 
T cell:T cell engagement (Fas:FasL interaction). These processes eliminate more than 
95% of effector CD8+ T cells, leaving 5% or less to become long-lived memory T cells51.  
Memory CD8+ T cells express a different phenotype and mediate different 
functions than naïve and effector T cells. Decreased expression of CD62L and variable C-
C chemokine co-receptor (CCR) type 7 (CCR7) expression reflect that these cells have 
undergone antigen priming and no longer require migration to peripheral lymph nodes for 
activation. Memory T cells gain expression of CD27, which is needed to provide co-
stimulatory signals when encountering antigen in the periphery. Memory T cells retain 
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expression of low affinity chains of IL-2R (CD122) and IL-7R (CD127), which are 
essential for survival, periodic homeostatic proliferation and antigen-driven 
proliferation44,52.  These proliferative episodes are intermittent and may be due to any of a 
multitude of factors including re-infection, stress or periods of decreased immunity. In 
terms of memory T cell numbers, the absolute number of effector T cells generated in the 
effector phase is the strongest determinant of how many memory T cells persist. 
However, how the effector cells are eliminated and the manner in which differentiating 
effector CD8+ T cells are maintained as memory cells, is also influential. Over time, 
memory T cells will decline in number if their survival requirements are not met.  
Conversely, persistence of memory T cells leads to further phenotypic changes. 
Expression of CD28, CD122, and CD127 decreases and with that, so does the capacity to 
activate pro-survival mechanisms such as telomerase expression53.  
From bone marrow to thymus to periphery, multiple regulatory processes 
involved in T lymphocyte proliferation, selection and survival ensure the sufficiency of 
adaptive immune responses against pathogens. However, once antigen is encountered, 
these T cells begin a slow progression towards the inability to proliferate, much like the in 
vitro fibroblasts described by Hayflick et al54. The associated decay in function is 
effectively defined by the extent of proliferation and differentiation previously 
undergone, which at least to a certain extent parallels biological aging. This feature of 
adaptive immune cells indicates that immune cell replicative senescence exists. 
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1.2.3 “Immunosenescence:” A Misnomer of Sorts… 
In aging tissues, senescence broadly manifests as a lack of capacity for self-
renewal, loss of organized function, decreased structural integrity and altered secretory 
profiles8. Fibrous tissue cell senescence has been thoroughly described, however, it is 
imperative to study senescence within the immune system as it comprises a large network 
within the body and is itself a tissue that ages and undergoes cellular senescence. The 
direct role of immune system senescence represents the largest unknown factor regulating 
the inflammaging-senescence relationship with unhealthy aging.  
Immunosenescence was a term used originally to refer to an elderly individual’s 
lack of an effective vaccine response55,56, but today the term continues to be used to 
represent multiple other features the immune system exhibits in old age.  This misnomer 
describes the gradual decline with age of naïve T cells and increases in adaptive memory 
T cells, increases in inflammation, and is somewhat unjustifiably associated with 
decreased resistance to infections and poor vaccine effectiveness57. Immunosenescence as 
defined by these popularized characteristics, applies only to macrophysiological changes 
in immune cell composition that occur with age, more specifically, an accumulation of 
cells representing adaptive immune memory. However, cells described by such broad 
criteria such as antigenic exposure comprise a largely heterogeneous population. 
Therefore, this view of immune senescence is not supported by aging at the level of 
individual cells, and thus, these organ level changes are not necessarily representative of 
the same underlying relationship with cellular senescence as seen in other tissues.   
Indices of immune cell senescence can be extrapolated from studies of 
senescence in other tissues.  The focus of our research will be restricted to the potential 
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development of chronic T cell senescence, rather than acute senescence, as the triggers 
are more readily related to aging. Therefore, we will outline a potential pathway to 
chronic senescence via the endogenous trigger of telomere erosion.  
1.2.4. Underlying Immune Senescence: End Replication in Memory T cells 
 As Hayflick et al. identified excessive passaging of fibroblasts as a trigger of 
cellular senescence, it became of paramount importance to recognize the many 
proliferative phases in immune cell development. As outlined in Figure 1.1, lymphocytes 
undergo intermittent periods of increased cell division between long phases of 
quiescence, depending on homeostatic needs, antigenic burden and levels of immune 
activating molecules in the periphery. In cases of exhaustive lymphocyte proliferation, the 
opportunity arises to study the end-replication problem, and subsequent telomere erosion, 
as a cause of chronic immune cell senescence.  
Like embryonic and stem cells, activated lymphocytes are one of the only 
somatic subsets of cells that selectively increase telomerase activity7. Most lymphocytes 
(excluding NK cells) originate from single cells selected in the thymus and the bone 
marrow based on affinity and specificity, and selected again in the periphery during 
primary antigenic exposure (denoted in Figure 1.1 as a single color representing a single 
“clone”). Therefore, all cells expressing the same antigen recognition receptor (TCR) 
theoretically stem from proliferation of a single “clone.” This concept, termed clonal 
expansion (denoted in Figure 1.1 by increased size of cells), specifies each round of 
proliferation as an opportunity for telomere loss. During clonal selection of naïve 
lymphocytes in the primary and secondary lymphoid organs, telomerase activity is 
elevated via IL-7:IL-7R or IL-2:IL-2R engagement to compensate for telomere erosion 
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through heightened cell division44. In the periphery, memory cells receiving antigenic 
stimulation also increase telomerase expression; however, this is not a conserved quality, 
as long-lived memory cells decrease their level of telomerase expression with each 
successive round of activation58 (Figure 1.1 d, e). Telomerase expression decreases 
virtually to zero in ex vivo mitogen activated memory T cells of the elderly, illustrating 
development of a large subset of T cells at risk for harmful telomere erosion59.  
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Figure 1.1. Factors involved in CD8+ T cell telomere maintenance throughout 
phases of cell differentiation. 
Lymphoid progenitor cells undergo cycles of quiescence and homeostatic proliferation 
(a), the latter being maintained by high levels of telomerase expression initiated by 
cytokines and growth factors, like IL-7, secreted by bone marrow stromal cells. 
Similarly, thymic stromal cells supply IL-7 ensuring telomerase expression during 
proliferative stages of positive and negative selection (b), and in antigen-naïve CD8+ T 
cells (c).   In the periphery, naïve CD8+ T cells encounter antigen, with successful 
activation triggering a proliferative response via an autocrine IL-2:IL-2R feedback 
loop and becoming CD8+ Teff cells (d). IL-2R triggers telomerase expression, however, 
continual activation reduces telomerase levels, leaving clonally expanded CD8+ Tem 
cells (e) with undetectable levels and at risk of critical telomere erosion and chronic 
senescence. IL, interleukin; Teff, effector T cell; Tem, effector memory T cell. 	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To investigate associations between immune cell telomere length and age-related 
illnesses, Cawthon et al. studied a large cohort of elderly patients stratified by leukocyte 
telomere length over a period of 15 years. The authors showed that individuals with the 
shortest leukocyte telomere lengths had the lowest rate of survival and the largest risk for 
developing age-related morbidities, most of which involved cardiovascular or immune 
complications60. Reflecting changes similar to those exhibited in elderly memory T cells, 
in vitro models employing successive rounds of mitogen stimulated T cell cultures 
recapitulate shortened telomeres, reduced proliferation, and altered cytokine generation61. 
These observations suggest a possible link between the telomere, exhaustive immune cell 
proliferation and in vivo immune senescence. Determining the exact role of telomere 
shortening in T cell functional decline with age could elucidate the mechanism validating 
use of the term immune, or more specifically lymphocyte, senescence and clarifying its 
role in inflammaging and age-related morbidity. Furthermore, identifying specific 
pathogens or other antigens that drive such progressive clonotypic expansion of memory 
T cell subsets, would be highly favorable for studies of immune senescence. 
1.3 Cytomegalovirus (CMV) Infection  
Human cytomegalovirus (HCMV), a member of the beta subfamily of 
Herpesviridae, infects ~75% of the developed world’s population62. Large and robust 
immune responses incorporating natural killer (NK) cells, inflammatory cytokines, and 
adaptive B and T cells contain virus levels after primary infection, but HCMV always 
results in persistent latent infection. In healthy individuals, reactivation from latency 
remains asymptomatic, however, in persons with a weakened immune system, such as 
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transplant recipients, cancer patients and those living with human immunodeficiency 
virus, bouts of viral reactivation can result in serious clinical issues, ex. CMV retinitis63. 
 1.3.1 CD8+ T cell Responses to CMV 
Adaptive immune responses to CMV have been extensively scrutinized, largely 
due to their atypical expansion into populations as large as 90% of total memory CD8+ T 
cells64. Although they are thought to relate to lifelong infection and periodic reactivation 
from latency, the mechanisms behind these expansions and how they are maintained are 
currently unknown and the subject of considerable debate. Even if it is unknown exactly 
how this prolific expansion of CMV-specific memory CD8+ T cells occurs, studying 
these cells and their associated maintenance could prove extremely useful for generating 
large, long lasting immune responses through vaccination.  
This unconventional expansion of CMV-specific T cells has been suggested as a 
model to study T cell senescence. This CMV-specific population appears to possess both 
an altered phenotype and functional disposition. Although adaptive immune senescence, 
and its associated characteristics is a highly understudied and currently speculative topic, 
strong associations between CMV-specific T cell frequencies, markers of replicative 
senescence and age potentially position CMV immunity as a primary driver of chronic 
immune senescence with potential linkage to age-associated morbidities.  
1.3.2 Atypical Clonality of CMV-specific CD8+ T cells 
	  
CMV specific T cells in a single individual are predominantly restricted to one 
or two Vα and Vβ families of the entire TCR repertoire65. Upon stimulation with CMV 
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antigen the majority of the response is mounted by a highly TCR-restricted population, 
with a single clone accounting for up to 40% of directed effector response(s) and up to 
15% of total CD8+ T cells66. These data suggest that large T cell compartments targeted 
towards CMV mostly originate from only a few naïve T cells selected early during 
primary infection. How this immunodominant clonality arises is incompletely understood, 
but research draws connections to higher avidity/affinity selection during viral episodes, 
or selective maintenance of clones early in primary infection. Despite lacking a clear 
mechanism, to create such a large oligoclonal population, this extensive clonal expansion 
must rely on successive rounds of cell division with eventual creation of an altered 
phenotype and functionally distinct subset of CD8+ T cells.  
1.3.3 Altered Phenotype of CMV-specific CD8+ T cells 
Long-term cultured CD8+ T cells lose CD27 and CD28 expression67, thus, it is 
assumed that CD8+ T cells, lacking expression of either in vivo, are long lived older cells. 
CD28- CD27- T cells dominate the CMV-specific subset68 and exhibit no dependence on 
costimulatory signals69, possibly relying solely on TCR engagement to manage antigen-
specific effector responses. Ex vivo stimulation of CD28- CD8+ T cells can restore 
expression of CD28, possibly to help initiate paracrine IL-2 activity once activated from 
quiescence.  However, this was not achieved in CD28- CMV-specific T cells as only 
transduced CD28 expression in CMV-specific CD8+ allowed successful paracrine IL-2 
activity and proliferation70.  Large fractions of CD28- CMV-specific CD8+ T cells with 
atypical activation feedback mechanisms could signify manifestation of a pre-senescent 
or senescent T cell population with altered transcriptional programming. 
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CMV-specific CD8+ T cells typically express CD5771, a cell surface marker 
associated with extensive rounds of proliferation and what is referred to as “terminal 
differentiation.” CD57 expression has been well studied on NK cells, identifying 
populations that apparently are more functionally mature and that demonstrate heightened 
cytotoxicity in both natural and antibody-dependent responses, while undergoing lesser 
proliferation when exposed to activating cytokines such as IL-12 or IL-1872. This 
increased CD57 expression is not only strongly associated with loss of CD27/2868, but 
also with loss of IL-2 family receptors CD122 (IL-2Rβ) and CD12773,74 (IL-7Rα), all 
predisposing towards a lack of proliferative capacity. Given the decreased expression of 
CD28, IL-7R, and IL-2R on CMV-specific CD8+ T cells and concomitant lack of a 
mechanism for telomerase induction, telomere erosion may underlie the replicative 
senescence exhibited by these cells.  
It should be noted that the majority of CD8+ T cells directed towards HCMV 
reside outside of the lymph nodes and are restricted to the circulation and tissue, a 
trafficking pattern reflected in the combination of chemotactic receptors expressed. 
CMV-specific CD8+ T cells lose expression of CCR7 during memory development, but 
gain CCR5 and CXC3 chemokine receptor 1 (CX3CR1)75,76. CX3CR1 and CCR5 
primarily home immune cells to sites of endothelial inflammation, normally in the initial 
stages of infection, via attraction to the chemokines: fractalkine (CX3CL1) and 
macrophage inflammatory protein (MIP) 1 α/β or RANTES, respectively77.  
CX3CR1:fractalkine activation pathways are also intimately involved in initiating pro-
survival mechanisms in memory T cells through increased expression of BCL-2/xL78.  
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Chronic activation of these pathways could potentially provide a mechanism for 
prolonged CMV-specific T cell survival and also possibly play a role in persistent 
inflammatory states of peripheral tissues in aging individuals.  
1.3.4 CMV-specific CD8+ T cells are Functionally Distinct  
The secretory profile and antiviral responses of effector CD8+ T cells are directly 
influenced by their stage of differentiation and the nature of the viral interaction. As 
frequencies of CMV-specific CD8+ T cells rise over time, presumably with intermittent 
viral reactivation, recurrent bouts of successful antigenic clearance reinforce a 
pronounced multi-functionality in CMV-specific CD8+ T cells optimized for effector 
function.  This multi-functionality involves diverse cytokine production and heightened 
cytotoxicity; however, they also exhibit lack of a robust proliferative response79.  
The production of IFN-γ and TNF-α are fundamental characteristics of the 
antiviral immune response mounted by CD8+ T cells. IFN-γ promotes T cell activation, 
enhances phagocytic activity of innate immune cells and primes infected host cells to 
increase expression of genes regulating antigen presentation80. TNF-α enhances the 
antiviral immune response in synergy with IFN-γ by directly triggering infected-cell death 
via the TNF superfamily of death receptors and by promoting CD8+ T cell survival and 
heightened IFN-γ and granule production in positive feedback cascades involving 
classical NF-κB signaling81. CMV-specific CD8+ T cells not only simultaneously produce 
both of these antiviral cytokines when exposed to antigen, but also produce them faster 
and at higher levels than other virus-specific effector CD8+ T cells82.  
	   	  
	   23 
In addition to antiviral cytokines, the secretory profile of CD8+ T cells engenders 
cytotoxic function through proximal secretion of serine protease granzymes and the pore-
forming protein perforin. CMV-specific cells again demonstrate not only higher 
immediate production of granzyme/perforin, but also a higher level of pre-assembled 
granules, establishing their capacity to exert prompt cytotoxic activity against CMV-
infected cells79,83.  During chronic human immunodeficiency virus (HIV) and/or hepatitis 
C virus (HCV) infection, a majority of CD8+ T cells recognizing viral epitopes produce 
antiviral cytokines such as IFN-γ, but have a reduced ability to lyse viral peptide-pulsed 
target cells. Those directed against CMV retain this function in the same host84. Selective 
maintenance of CMV-specific T cells with these features could represent adaptation 
towards greater viral control or an acquired secretory feature (SASP) representative of 
replicative T cell senescence. 
Some studies of multifunctional CD8+ T cells have incorporated IL-2 production, 
in addition to IFN-γ and TNF-α, as a third functional cytokine to gain insight on virus-
specific T cell exhaustion. These studies have shown that simultaneous production of all 3 
cytokines is generally associated with successful containment of viral or bacterial 
infections, like M. tuberculosis and even HIV85,86. Profiling of CMV-specific CD8+ T 
cells shows that up to 75% are triple-cytokine producers, with as low as 2% of responding 
T cells producing only one cytokine (predominantly IFN-γ)87. These mono-cytokine 
producing T cells, although low in frequency, showed the highest IL-2/IL-2R expression 
and proliferation with Ag exposure. Poly-functional CD8+ T cells that respond with 
multiple cytokine production showed little production/expression of IL-2/IL-2R and 
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underwent significantly less proliferation, despite high production of IFN-γ and TNF-α69. 
High effector functions and low proliferative capacity could potentially illustrate the 
phenotype acquired by CMV-specific CD8+ T cells as they progress towards T cell 
senescence.  
A key feature in contraction of expanded CD8+ T cell populations is initiation of 
apoptosis. Studies comparing activation induced cell death (AICD), a mode of T-cell 
limiting apoptosis, in various antiviral T cell subsets suggest that CMV-specific cells 
harbour high levels of anti-apoptotic proteins B-cell lymphoma (BCL)-2 and BCL-xL, 
compared to HIV and HBV-specific CD8+ T cells in the same host88. Normally 
upregulated during memory cell formation and triggered by CD28 or IL-2R engagement, 
levels of these anti-apoptotic proteins remain elevated in CMV-specific CD8+ T cells 
independent of receptor ligation78. Ex vivo studies of CMV-specific CD8+ T cells indicate 
that these T cells increase BCL-xl/2 protein expression in response to antigenic 
stimulation, in comparison to HIV-specific CD8+ T cells,  and remain resistant to a 
multitude of apoptotic triggers including protein kinase C (PKC) inhibition, FasL 
engagement and growth factor withdrawal89. Development of these pro-survival factors 
could arise due to unique features of CMV infection, but it is clear that CMV-specific T 
cells are long lived and become apoptosis-resistant, creating another potential hallmark 
feature of CMV-associated T cell senescence.  
CMV-specific CD8+ T cells represent a population that could be used as a model 
to understand T cell senescence. This particular effector memory subset possesses 
heightened functional specialization, which could represent features of an adaptive 
	   	  
	   25 
immune cell SASP. CMV-specific T cells undergo extensive in vivo proliferation, 
however, they exhibit limited ex vivo replication, potentially representing subset-wide cell 
cycle arrest. Effectively dysfunctional in clonal retraction in vivo, this feature of CMV-
specific T cells is paralleled ex vivo in their high resistance to apoptosis upon antigen 
stimulation.  Possession of similar traits to those observed for senescent cells in tissue 
suggests that CMV-specific T cells could be a senescent immune cell subset and, 
therefore, accumulation of such could potentially drive relationships between CMV and 
age-associated morbidities.  
1.4 Aging with CMV 
As previously stated, aging is strongly associated with declining physiological 
function and whether due to decreased immunosurveillance or increased exposure, is 
strongly associated with prevalence of CMV infection90.  In a study of a representative 
population of the developed world (n = 21 639) the prevalence of CMV infection rises 
from 36% in children under 11, to 91% in adults over the age of 8091. In all age groups, 
CMV infection creates signature alterations in adaptive immune memory profiles, 
however, in the old elderly, these changes related to CMV infection are associated with 
increased all-cause mortality92.  
Despite this clear association between CMV infection and unhealthy aging, the 
exact mechanism underlying this relationship remains unknown.  It has been suggested 
that CMV infection accelerates the natural aging process by affecting immune system 
aging. Although it is governed by a multitude of known and unknown factors, the natural 
course of aging of the adaptive immune system primarily reflects declining thymic 
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function and immune stresses, ultimately progressing towards a steady state of immune 
senescence in the old elderly. This introduction will now focus on association of CMV 
infection with previously described features of immune senescence, including reduced 
clonal diversity in the T cell repertoire, increased inflammation, and onset of multiple 
age-related morbidities.  Given the changing demographic of most populations and the 
social and economic costs of unhealthy aging, understanding how CMV influences 
unhealthy aging, and ultimately morbidity and mortality, is crucial for health-related 
research. 
1.4.1 CMV-associated Repercussions on T Cell Diversity 
Thymic involution reflects structural and functional degeneration of the thymus 
that begins around puberty and continues into old age.  Thymic tissue gradually is 
replaced with adipose tissue, greatly reducing thymic output and, therefore, restricting the 
majority of naïve T cell production to prepubescent stages. This age-associated decline in 
thymopoiesis drives the ratio of naïve to memory T cells down with age and antigen 
exposure, and is, therefore, largely responsible for the immune profile seen in old age93 
and is a natural contributor to the common phenotypic profile of immune senescence.  
Given the extensive thymic activity early in life, older children and even adults 
are generally considered to be unaffected by its surgical removal. However, a study by 
Sauce et al. showed that this actually holds true only if a thymectomized child is 
seronegative for CMV94. Monitoring T cell dynamics in thymectomized CMV-
seropositive children showed progressive development of the characteristically low 
naïve:memory T cell ratios normally exhibited in old age. Deep-sequence profiling of the 
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TCR repertoires of these children also showed substantial restriction of TCR sequences, 
with a majority of sequences complementing immunodominant CMV antigens, another 
feature of immune senescence observed in the elderly95. These results represent an 
acceleration of effects occurring with CMV infection and natural thymic decline, with 
TCR diversity analyses of healthy CMV-seropositive adults revealing 33% reductions in 
TCR diversity compared to seronegative individuals of the same age71. Although not all 
the specific expansions were demonstrated to be CMV-epitope specific, the results of 
these studies clearly support the supposition that CMV infection reduces TCR diversity 
over time, to a much greater extent than natural aging alone.  
To assess the impact of CMV infection on immune aging in an animal model, 
young mice were infected with MCMV and monitored longitudinally to assess age-
related changes in immune proficiency. Challenges with secondary infections showed that 
successful pathogen clearance was more frequent in uninfected mice, however, rates of 
success did decrease with age in both groups of mice. MCMV-infected mice showed 
equivalent pathogen clearance when young, but their clearance rates declined at younger 
ages and more dramatically than in the uninfected mice96.  TCR repertoire analysis 
indicated that the effects of MCMV-infection parallel those seen in human studies with a 
stark reduction in overall diversity, and a majority of expanded clonotypes being specific 
for MCMV epitopes. Interestingly, the MCMV-infected mice also suffered higher all-
cause mortality and a shorter lifespan, suggesting that MCMV infection is a useful animal 
model for accelerated aging96. The mechanism by which CMV infection affects this 
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process remains speculative however, it is crucial to consider the role of extensive CMV-
mediated clonal T cell expansion and explore its potential links to inflammaging. 
1.4.2 CMV-associated Alterations in Systemic Inflammation  
High frequencies of functionally intact CMV-specific CD8+ T cells reveal the 
potential for cycles of inflammation, immune activation and homeostatic proliferation to 
contribute to aging of the immune system. “Healthy” CMV seropositive individuals have 
low-grade chronic inflammation characterized by increases in type 1 cytokines, growth 
factors, IL-6, and C reactive protein (CRP)97. Type 1 cytokines, such as IFN-γ, TNF-α, 
and IL-2 are a group of cytokines that facilitate cellular immunity, driving naive CD4+ T 
cells to differentiate into Th1 cells while maintaining and reinforcing antiviral CD8+ T 
cell immunity. Increased levels of these activating cytokines in the periphery could drive 
non-specific activation of nearby T cells opening the way for positive feedback loops 
closely resembling those suspected to be involved in paracrine senescence. CRP, as an 
acute phase protein produced in the liver due to increased IL-6, IL-1β or TNF-α, is 
elevated during acute infection, however, sustained increases occur in chronic 
inflammatory diseases and are indicative of increased risk for cardiovascular disease98. A 
study by van de Burg et. al  associated serum levels of IFN-γ with CRP during CMV 
latency raising suggestions that the magnitude of CMV-specific T cell immunity is 
associated with increased risk for cardiovascular disease97. In vivo studies of vascular 
inflammation and arterial damage indicated no strong associations between detectable 
CMV DNA and CRP or other signs of cardiovascular risk77, suggesting factors other than 
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CMV replication itself, such as CMV-immunity potentially play roles in vascular 
damage. 
During arterial disease, cells within the inflamed vasculature can secrete high 
amounts of IL-6 and CX3CL1 (fractalkine) in attempts to communicate distress and 
promote immune-mediated clearance99. To investigate the possible link between CMV 
immunity and cardiovascular damage, Bolovan-Fritts et al exposed HCMV-infected 
endothelial cells to syngeneic lymphocytes from CMV-positive donors. While only 
minimal damage appeared to be directly due to CMV replication, blocking the 
CX3CL1:CX3CR1 interaction reduced overall endothelial cell death by 3-fold100. Since 
CX3CR1 expression is high on CMV-specific CD8+ T cells, chemokines produced by 
endothelial cells may be intrinsically involved in invoking cell damage in response to 
CMV replication. Since CMV-immunity increases with age, it is reasonable to implicate 
the immune response against CMV as a major component of vascular degeneration, 
inflammation and increased age-associated cardiovascular risk. This specific situation of 
potential tissue senescence arising through multiple rounds of endothelial cell 
proliferation, due to viral replication and tissue homeostasis, with an exaggerated immune 
response leading to tissue damage could, provide a major link between CMV infection 
and pathogenesis of age-associated cardiovascular disease.  
1.4.3 CMV and Risk of Age-related Morbidity 
Despite extensive literature addressing the effect of CMV infection on both the 
adaptive immune system composition and pathogenesis of multiple age-related 
morbidities, none have effectively revealed a mechanistic connection. Pawelec et al. of 
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the Swedish OCTO and NONO longitudinal population studies, directly associated CMV 
infection with increased mortality in the elderly, but only alluded to immune senescence 
as a potential cause. The studies have uncovered immune parameters such as decreased 
ratios of naïve to memory T cells, decreased T cell repertoire diversity and increased 
levels of systemic inflammation, related to increases in mortality56,71,92. More specifically, 
studies in which the cause of death is identified have consistently shown increases in 
morbidity and drawn attention to dramatic increases in inflammation and cardiovascular-
associated disease in CMV-infected elderly101,102. 
CMV-serostatus is linked to increased risk of multiple age-associated 
morbidities, especially atherosclerosis, diabetes, and cardiovascular disease103. CMV-
seropositivity is associated with a 4-fold increase in new diabetes cases in transplant 
recipients, independent of age, a risk not seen with any other viral infection104. The 
inflammatory nature of diabetes, compounded by the apparent increase in inflammation 
that accompanies CMV infection, raises the risk of atherosclerotic events much higher in 
diabetic individuals and intensifies clinical repercussions29,105. In a later study exploring 
the additive nature of diabetes and CMV infection with regard to cardiovascular risk, 
increases in anti-CMV IgG titres paralleled increases in the frequency and severity of 
atherosclerotic events106. The systemic inflammation seen during CMV infection has been 
suggested to play an exacerbating role in other autoimmune or chronic inflammatory 
conditions such as rheumatoid arthritis (RA), systemic lupus erythematosus, and systemic 
sclerosis107. Higher circulating levels of anti-CMV Ig have been associated with increased 
pathophysiological events during autoimmune diseases, often requiring surgical 
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intervention108–110. Pro-inflammatory CMV-specific CD8+ T cells have been isolated from 
the synovial fluid of RA-affected joints and HCV-infected fibrotic livers111,112. CMV 
infection clearly plays a role in heightening risk of cardiovascular, autoimmune and 
metabolic disease, most likely through increases in systemic inflammation. 
It should be noted that although these studies have used populations spanning 
generations, the majority have focused on the elderly or those living with chronic 
inflammation. A select population frequently identified as facing repercussions of 
immune senescence, are persons living with chronic human immunodeficiency virus 
(HIV) infection113. This population has an immune background that allows for dramatic 
growth of CMV-specific immunity in a virtually age-independent manner. Understanding 
the interaction between CMV and HIV-related immune parameters accelerating the 
pathogenesis of immune senescence during HIV infection could also help identify key 
immunological factors involved in unhealthy aging of the general population  
1.5 Aging with CMV and HIV 
	  
It is now a common assumption that those living with HIV and having access to 
antiretroviral therapy (ART) will effectively suppress viral replication and prevent the 
onset of acquired immunodeficiency syndrome (AIDS). With the initial advent of ART, 
HIV-infected individuals remained subject to AIDS-defining conditions such as Kaposi’s 
sarcoma, pneumocystis pneumonia, wasting syndrome, toxoplasmosis, a host of 
autoimmune conditions and high rates of opportunistic infections114. Through effective 
combination ART (cART), the HIV-infected population in developed countries has 
experienced a large decrease in the aforementioned conditions, progression to AIDS, viral 
	   	  
	   32 
transmission and infectivity115. Despite reaching this landmark in HIV treatment, cART 
does not restore all aspects of health.   
Longitudinal studies following HIV-infected individuals on cART, like that by 
Samji et al., have demonstrated dramatic increases in life expectancy116. The high 
effectiveness of cART and resulting increases in longevity for HIV-infected individuals, 
however, allows for increased frequencies of development of other adverse conditions not 
associated with progression to AIDS. Non-AIDS defining conditions like diabetes, 
cancer, cardiovascular disease, hypertension, bone disease, and most relevant to this 
project, immune senescence, can occur up to 15 years earlier during HIV infection than in 
the general population117. This increased risk for non-AIDS defining conditions follows a 
pattern similar to that of the more elderly non-HIV-infected population118, suggesting that 
even well-treated HIV infection might accelerate the aging process. Given that 
accumulation of senescent cells is an intrinsic feature of aging, it is imperative that the 
age-associated regulatory processes involved in limiting senescence, including how the 
immune system is involved, become better elucidated in the context of HIV infection. 
Early studies of CMV infection and its effect in HIV-infected individuals 
suggested it was a cofactor accelerating progression to AIDS in the pre-ART era. These 
studies primarily view CMV viremia as an AIDS-defining feature, and implied that CMV 
replication translates into increased inflammation, T cell death and an increased risk of 
opportunistic infections (not including CMV re-infection)63. However, this role of CMV 
as an opportunistic infection, in the context of HIV infection, differs in nature from the 
proposed deleterious age-associated effects CMV has on the immune system and 
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inflammation that occur in elderly HIV-negative individuals. Therefore, the burden of 
CMV infection and its effect on the immune system, its senescence and other sources of 
inflammation, should be re-addressed in order to elucidate a potential mechanism in the 
“premature” aging processes seen during HIV infection. 
1.5.1 HIV-associated Inflammation 
Inflammation that occurs despite ART-treatment renders virally supressed HIV 
infection a chronic inflammatory disease. Suggested contributors to the inflammatory 
landscape include microbial translocation and chronic immune activation, HIV 
replication, ART regimens and their side effects. However, it has recently also been 
suggested that unknown dysfunctional immune-regulatory components play a central 
role119, including immune senescence and immune cell SASPs. 
IL-6 levels, reportedly 40-60% higher in HIV-infected individuals than the 
general population, correlate with HIV viral load, CD4+ T cell nadir and duration of HIV 
infection120. These levels peak during primary and early chronic HIV infection and 
although they decline with effective treatment, remain chronically higher than those of 
age-matched non-HIV-infected controls118. This peripheral inflammatory cytokine and 
downstream respondents like CRP can be twice as high in treated HIV-infected 
individuals as in the age-matched uninfected population121. These relatively low-grade 
increases in the concentrations of such pro-inflammatory cytokines are comparable to 
those occurring in aged (>70 years old) uninfected controls23. Although it is the most 
common marker for increased risk, it remains undetermined whether IL-6 elevation is 
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directly involved in the onset of the age-related morbidity in either group or if it is simply 
the most common marker of systemic inflammation.  
Immune activation markers such as TNF-α, IFN-γ, and β−2 microglobulin 
(B2M) can all be elevated, even during treated HIV infection122,123. Irrespective of the 
underlying cause or route of generation, chronic increases in activating cytokines offers a 
potential explanation for the perpetually activated phenotype of CD8+ T cells in HIV-
infected individuals (CD38+ HLA-DR+ CD28- CD27-)124,125. This chronic activating 
milieu could drive non-specific expansion of CD8+ T cells, and accelerate the telomere 
attrition observed in CD8+ T cells during HIV infection.  
Inflammation and chronic immune activation are both associated with 
development of atherosclerosis, a major risk for the elderly. Recently, this risk was also 
implied in CMV+HIV+ individuals in a study of CMV/HIV co-infected subjects. Hsue et 
al. showed that the frequency of activated CMV-specific T cells, rather than levels of 
CRP or other markers of immune activation was associated with increased intima 
thickness, a marker of risk for development of atherosclerosis121. Pro-inflammtory IL-1 
family cytokines, like IL-1α/β, are found in short-term culture supernatant of primary 
tissue samples (renal, adipose, mucosa, liver, vasculature) taken from HIV-infected 
individuals with high risk for cardiovascular disease126,127. Several studies involving 
ART-treated individuals state that production of these cytokines is due to dysfunctional 
immune cells, since no detectable HIV-RNA was identified (however, CMV was not 
included these studies)128. Thus, although CMV-related immunity may directly affect this 
	   	  
	   35 
pro-atherogenic environment, it remains generally understudied as a vascular health 
factor in HIV infection.  
Non-specific cytokine mediated immune activation and proliferation during HIV 
infection could increase the frequency of replicatively senescent effector CD8+ T cells 
and fuel development of a comprehensive, yet uncharacterized, SASP phenotype with 
inflammatory components.  Given the association of HIV infection and “premature 
aging,” especially in the context of CMV infection, the role of an immune cell SASP and 
characterization of further complications of such, needs to be further addressed.  
1.5.2 CMV/HIV Co-infection Impacts on T Cell Diversity 
The most degenerative feature of progressive HIV infection is the decline of the 
adaptive immune system, namely selective loss of CD4+ T cells. Untreated HIV infection 
is highly thymotoxic through direct and indirect effects of viral infection and through 
immune responses related to HIV infection. In ART clinical trials, researchers observed 
that a phenomenon known as “immune reconstitution” could occur, where low-level 
thymic activity and division of surviving/pre-existing immune cells lead to recovery, at 
least to some extent, from immune losses occurring during untreated infection129. Despite 
regaining high numbers of CD4+ T cells during treatment, full recovery of immune 
function rarely occurs. This was reflected in a study by van den Berg et al., which 
identified the need to revaccinate HIV-infected individuals to restore hepatitis B virus 
(HBV) immunity after ART-treatment, demonstrating loss of -or loss of maintenance of- 
CD8+ T cell memory responses130. HIV-infected individuals also showed reduced vaccine 
induced memory development, often generating only short-term CD8+ T cell responses 
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against vaccine-encoded epitopes131. These studies show that despite the apparent 
reconstitution of lymphocyte numbers, this does not fully restore immune function, as 
illustrated by inconsistent CD8+ T cell responses to secondary pathogens in HIV 
infection.  Although the exact reasons for this are unknown it could play a role in the 
reduced CD8+ T cell memory responses reported during treated HIV infection. Treated 
HIV-infected individuals often possess higher frequencies of CMV-specific CD8+ T cells, 
than the general population132,133.  
HIV infection is associated with increased absolute numbers of CD8+ T cells133, 
and much like the CMV-infected elderly134, these cells often express a memory 
phenotype. This persistent increase in CD8+ T cells occurs despite effective treatment that 
reduces HIV replication and allows restoration of CD4+ T cell counts133. HIV-infected 
individuals also show a 10-fold decrease in overall TCR diversity, particularly in the 
CD8+ T cell compartments dedicated to memory129, compared to the general population 
suggesting extensive clonal expansion or selective homeostatic proliferation. CD8+ T 
cells in individuals treated for their HIV infection broadly show increases in CD57 
expression, decreases in co-receptor expression (CD27, CD28), and a reduced capacity to 
proliferate and mount effector functions ex vivo compared to CD8+ T cells isolated from 
uninfected individuals68,132 . Increased numbers of CD8+ T cells, acquisition of a 
senescent phenotype and decreased CD8+ TCR diversity are all associated with increases 
in non-AIDS related diseases118,129,135. It is suggested that these deficits in the CD8+ T cell 
compartment during HIV infection signify premature or accelerated immune senescence 
and mostly occur independent of age. Although generally similar to the immunological 
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abnormalities associated with the extensive clonal expansion of CMV-specific T cells in 
aged non-HIV-infected individuals, the mechanistic connection between these similar 
phenotypes remains under-examined. 
With such a large increase in CD8+ T cells and the marked reduction of CD4+ T 
cells, it is common clinically to use the ratio of CD4+/CD8+ T cells as a surrogate marker 
for immune competence in HIV infection. When this ratio falls below 1.0, signifying 
increased expansion of CD8+ T cells in relation to CD4+ T cell recovery, there is a higher 
associated risk for non-AIDS related events117. Early-exposed HIV-infected children co-
infected with CMV have higher frequencies of terminally differentiated CD8+ T cells and 
lower CD4:CD8 ratios, when compared to CMV-seronegative children, regardless of 
detectable CMV DNA or HIV RNA in peripheral blood118,135. This observation indicates 
that CMV infection compounded by HIV infection produces an age-independent 
expansion of CD8+ T cells. Barrett et al. further illustrate this interaction between CMV 
and HIV infection, showing that CMV-seropositive HIV-infected individuals have lower 
CD4:CD8 T cell ratios, independent of age and HIV viral load136. CMV infection clearly 
skews the CD8+ T cell repertoire towards an immune senescent phenotype, in an age-
independent manner during HIV infection.   
1.5.3 Telomere Erosion and Aging in HIV Infection 
To investigate the role of HIV infection in development of immune senescence 
and the aging processes, leukocyte telomere length (LTL) was used as a marker of 
cellular replicative history. The degree of telomere erosion is markedly pronounced 
during HIV infection, with general LTL comparable to that of uninfected individuals’ 
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decades older. By compartment, CD8+ T cells possess shorter average telomere lengths 
than CD4+ T cells, indicating greater overall proliferation of CD8+ T cells in HIV 
infection137. Effector memory CD8+ T cells that re-express CD45RA, a subset comprised 
of pro-inflammatory terminal effector T cells, have shorter telomeres than other memory 
subsets87. To address the high genetic heterogeneity in cohorts screened for LTL, studies 
of HIV-discordant monozygotic twins showed that uninfected siblings had longer 
telomeres in their CD8+ T cells. This effect was not apparent in CD4+ T cells, indicating 
that the environment and operative mechanisms in HIV infection only override specific 
age and genetically determined effects on telomere erosion in CD8+ T cells138. It is 
important to note that CMV infection was not taken into consideration for these studies, 
despite HIV-infected individuals having a higher rate of CMV infection139.  LTL is also 
associated with the duration of untreated HIV disease and lower CD4+ T cell nadir140, the 
same factors associated with decreased TCR diversity, suggesting a relationship between 
LTL and TCR diversity, potentially through the effects of CMV-related T cell clonal 
expansion. LTL in HIV-infected populations is inversely associated with increased risk of 
COPD, heart disease, type 2 diabetes, cancer, and a host of other age-associated 
morbidities141, reflecting the similar relationship occurring in older CMV-infected HIV-
negative populations. These associations appear to suggest clonal expansion as a primary 
driver of lymphocyte telomere erosion, and affects the clinical presentation of age-related 
diseases in HIV infection. 
A predominant feature of the aforementioned studies is that the cohorts consisted 
mainly of ART-treated participants, essentially excluding active HIV replication as a 
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mechanism of inflammaging. Increases in CMV-specific CD8+ T cells, increases in 
immune activating cytokines or CRP, were all found to be consistently greater in HIV-
infected individuals, regardless of specific ART regimen or duration of viral 
suppression142. Despite this, there is considerable debate over the role of ART in 
accelerated aging of HIV-infected individuals.  Many antiretroviral drugs, particularly the 
older reverse transcriptase inhibitors, exhibit in vitro telomerase inhibition and have 
themselves been suggested as contributors to immune senescence143. LTL in HIV+ 
individuals does not change in relation to ART regimen, as reported in a study by 
Solomon et al, who longitudinally studied patients on various ART-regimens to address 
suggestions of ART-inhibition of telomerase144,145. Multiple studies of HIV-infected and 
uninfected adults consistently show that telomerase activity is virtually undetectable in 
CD8+ T cells, therefore, ART should have little or no effect on telomere shortening, 
thereby implicating clonal expansion and homeostatic proliferation as the main cause of 
telomere erosion both in adults living with HIV and the general population144. While 
ART-toxicity and telomerase inhibition is potentially a contributor to telomere attrition in 
vitro, it is highly unlikely to induce senescence in immune cells in vivo. Accelerated 
telomere length decline, more-so than inhibition of telomerase activity, places the focus 
on drivers of expansion and exhaustive proliferation, such as CMV infection, as causes of 
senescence within the CD8+ T cell population during HIV infection.  
1.6 Exploring Aspects of Senescence in a HIV/CMV-co-infected Population 
The protective role of the adaptive immune system in relation to aging processes 
is assumed to be in aiding senescent cell clearance, therefore, this regulatory role could be 
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compromised during HIV infection. The observed deficits in adaptive immunity, during 
HIV and CMV infection, and accompanying increased prevalence of age-associated 
pathologies, provide a unique setting within which to study the progress and impact of 
senescent cell accumulation. Decreased immune surveillance may allow cells to not only 
become chronically senescent, but also persist at high levels within tissues. This increases 
the likelihood of SASP-induced paracrine senescence of nearby cells. Peripheral CD8+ T 
cells homing to this inflamed and highly stimulatory tissue could further fuel this 
feedback loop of activation, expansion and telomere attrition. Therefore, not only are 
immune cells indirectly contributing to senescent cell accumulation, but also could 
themselves reach senescence through this process, propagating a deleterious cycle that 
promotes “premature aging” in HIV infection. 
We speculate that clonal expansion of CMV-specific CD8+ T cells during HIV 
infection results in exhaustive proliferation and places this select T cell subset most 
proximal to replicative senescence. In line with this, we predict that this subset will have 
shorter telomeres than the general lymphocyte population, than other CD8+ T cells, and 
other non-CMV-specific terminally differentiated CD57+ CD8+ T cells.  
To test this, we will measure and compare telomere lengths of CD8+ T cell 
subsets within the same individual to control for age and the highly inheritable genetic 
influence on telomere length. To assess whether replicative senescence is selectively 
approached by CMV-specific CD8+ T cells, we will measure and compare the average 
telomere length of HIV-specific CD8+ T cells in the same individual.   
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 We will employ a combination technique, flow-FISH, comprised of 
fluorescence in situ hybridization (FISH) and flow cytometry to simultaneously quantify 
telomere lengths and identify antigen–specific CD8+ T cells. The FISH procedure 
requires a high temperature and formamide treatments, therefore, we will develop a three-
colour temperature-resistant fluorochrome-conjugated antibody panel to identify IFN-γ 
producing CD57+CD8+ T cells. The addition of a fourth colour, representing the 
fluorochrome-conjugated oligomer quantifying telomere repeat length, will complete the 
panel and allow us to properly discriminate subsets based on extracellular and 
intracellular proteins, as well as telomeric DNA content.  
To identify any association between CMV-specific CD8+ T cell telomere length 
and systemic inflammation, a suspected feature of immune senescence, we will quantify 
plasma levels of cytokines, chemokines and acute phase proteins. Plasma concentrations 
of IL-1β, IL-6, TNF-α, fractalkine (CX3CL1), and CRP will be compared between 
individuals distinguished by CMV serostatus.  We will also assess biological age as a 
variable to determine if chronological aging outweighs the effects of CMV-related clonal 
expansion in HIV-infected individuals.  
If CMV infection is a major factor in shifting the adaptive immune system 
towards chronic senescence, the most dramatic effects should be revealed in the context 
of HIV infection, where increased chronic inflammation and exaggerated anti-CMV 
immune responses may optimally support progressive age-independent chronic immune 
senescence.   
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2 Methods 
2.1 Ethics 
All subjects provided informed consent for whole blood collection, 
immunological studies and (when available) researcher access to medical laboratory 
records. The Newfoundland and Labrador Health Research Ethics Authority approved 
this study. 
2.2 Study Subjects 
Study subjects infected with HIV were recruited through the Newfoundland and 
Labrador Provincial HIV Clinic. HIV-infected subjects were screened for HIV-1 
antibodies via ELISA and the presence of anti-HIV antibodies was confirmed by western 
blot. Routine clinical assessments; with lymphocyte subset analysis, including CD4+ and 
CD8+ T cell counts, and viral load were performed at least once every six months.  
2.3 Peripheral blood mononuclear cell (PBMC) isolation 
Whole blood (20 mL) was collected by forearm venipuncture into vacutainer 
tubes containing acid-citrate-dextrose (ACD) anticoagulant. Plasma was collected 
following centrifugation at 400g (10 min, room temperature (RT), aliquoted immediately 
and stored at -80°C. Packed cells and buffy coat were diluted to two times the original 
blood volume with phosphate-buffered saline (PBS), then layered over Ficoll-Hypaque 
density gradient separation medium (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) 
and centrifuged at 400g (30 min, RT) with the brake off. Interface PBMC were collected, 
washed once in PBS with 1% fetal calf serum (FCS, Invitrogen, Carlsbad, CA, USA) and 
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resuspended in lymphocyte medium comprised of RPMI 1640 with 10% FCS, 100  IU/mL 
penicillin, 100  µg/mL streptomycin, 2  mM L-glutamine, 10  mM HEPES buffer solution 
and 2 x 10−5 M 2-mercaptoethanol (all from Invitrogen).  
2.4 PBMC Cryopreservation/Thawing 
Freshly isolated PBMC were resuspended in freezing medium, comprised of 
lymphocyte medium supplemented to 20% FCS, with 10% dimethyl sulfoxide (DMSO, 
Sigma, St. Louis, MI, USA), at a minimum of 1 x 107 cells/mL and cooled at 1°C/min 
overnight reaching -80°C. Frozen PBMC were transferred to and maintained in liquid 
nitrogen until required. To thaw cells, cryopreserved PBMC were immediately immersed 
in 37°C water bath, gently agitated until almost thawed, then immediately transferred 
into, and washed 3 times in, 10 mL lymphocyte medium. Cells were resuspended in 
lymphocyte medium at 2 x 106 cells/mL and allowed to recover overnight at 37°C, 5% 
CO2. Cells were counted after recovery and all PBMC used were >70% viable by trypan 
blue exclusion.  
2.5 Peptide Stimulation of PBMC to Identify Antigen Specific CD8+ T cells 
Aliquots of 2 x 106 PBMC in 1 mL lymphocyte medium were stimulated with 
overlapping CMV-pp65 (0.5 µg/mL) and immediate early-1 (IE-1) peptides (0.5 µg/mL 
Miltenyi Biotec, San Diego, CA, USA), or overlapping HIV-1 Nef (1.0 µg/mL) and Gag 
(1.0 µg/mL) peptides (NIH AIDS Reagent Program, Germantown, ML, USA), for 60 
minutes at 37°C (5% CO2). Brefeldin A (Sigma-Aldrich, St. Louis, MO, USA) was added 
to a final concentration of 10.0 µg/mL to inhibit cytokine secretion and PBMC were 
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incubated at 37°C 5% CO2 for an additional 4 hours after which they were immediately 
processed. The stimulated PBMC were first washed and stained for surface markers, 
using fluorescein isothiocyanate (FITC)-conjugated anti-human CD57 (TB03, Miltenyi-
Biotec) and Quantum Dot (QD) 705-conjugated anti-human CD8 (3B5; Invitrogen). 
Samples were kept in the dark from this point on. Intracellular staining of PBMC was 
done using allophycocyanin-conjugated anti-human IFN-γ (4S.83, eBioscience, San 
Diego, CA, USA), after fixation and permeabilization using InsideStain (Miltenyi 
Biotec), according to manufacturer’s instructions. Washes between steps were with flow 
buffer (PBS supplemented with 5 mM ethylendiaminetetraacetic acid (EDTA, Sigma-
Aldrich), 0.5% FCS, 0.2% sodium azide, pH 7.2). Cells were resuspended in 1% 
paraformaldehyde (PFA) and were analyzed after acquiring a minimum of 1 x 105 events 
per sample within 48 hours, using a FACSCalibur Cell Analyzer (BD Biosciences, 
Mississauga, ON, CA). Isotype and fluorescence minus one (FMO) controls were used, 
when required, during optimization of multi-parametric panels. Unstained and 
unstimulated controls were used to account for background and endogenous activation, 
respectively.  
2.6 FlowFISH Telomere Length Quantification of Antigen-specific CD8+ T 
cells 
2.6.1 Overview 
The flow-FISH protocol is a technique that combines the high throughput and 
multi-parametric versatility of flow cytometry with cytogenetic fluorescence in situ 
hybridization techniques. The FISH technique is used in this instance to identify and 
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quantitate telomeric DNA repeats. Use of a fluorochrome-conjugated complement 
peptidyl-nucleic acid (PNA, (CCCTAA)3) enables assessment of telomere repeat 
frequency, and thus length by flow cytometry. This FISH procedure uses PNA over 
oligonucleotides, for its high binding affinity in smaller sized oligomers, which results in 
less mismatch binding. The observed mean fluorescence intensity corresponds to the 
amount of fluorochrome-conjugated PNA bound during the hybridization process. 
Telomere length is first calculated relative to a control cell line (1301 T cell leukemia, 
Sigma-Aldrich) with extremely long telomeres (23,480 base pairs), that acts as an internal 
standard. From this relative value, the known telomere length of the 1301 cell line allows 
approximate telomeric base-pair calculation of sample(s) of interest. Building off this 
procedure, I developed and optimized a multiplex protocol to identify and phenotype 
various T cell subsets of interest and compare their average telomere length(s).  
We first attempted to demonstrate efficacy of the flow-FISH assay by using a 
commercial (Dako) FITC-conjugated PNA-probe (already in hybridization solution) to 
quantify telomere length (TL) of whole peripheral blood mononuclear cells (PBMC) 
(data not shown). However, as illustrated by Akbar et al. (2015), the use of a commercial 
kit limits the optimization of fluorescent multiplexing87. Therefore, we quantified TL 
using an in-house Cy3-conjugated PNA system (Panagene, South Korea) with Cy3-probe 
preparations and hybridization solutions adapted from Akbar et al (Figure 2.1). 
  
	   	  




Figure 2.1. Flow cytometry events and Cy3-TelC MFI of gated subgroups. 
Identification of an internal long telomere positive control, the 1301 T leukemia cell 
line, using FSC vs SSC event gating or solely Cy3-TelC PNA probe fluorescence. 
(FSC, forward scatter; SSC, side scatter; TelC-Cy3, Telomere C-rich peptide-nucleic 
acid cyanine-3 conjugated probe. 	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Given the high temperature of DNA denaturation, fluorochromes and antigen 
targets intended to be incorporated in the flowFISH assay must be either be high 
temperature resistant or have the antigen-antibody interaction stabilized via 
bissulfosuccinimidyl suberate (BS3)-crosslinking. This process creates N-
hydroxysulfosuccinamide (NHS) amide bonds with primary amines of antibody lysine 
residues, increasing stability of antigen-antibody-conjugate complexes to high 
temperatures. 
We developed our flowFISH assay using FITC-conjugated antibodies, 
previously shown to have high temperature resistance, QDot-, and APC-conjugated 
antibodies and incorporated the crosslinking procedure as an essential step to maximize 
signal persistence. We first individually tested each fluorochrome (Figure 2.2) to validate 
preservation of fluorescent signals and to identify any spectral overlap or compensation 
issues. No issue developed that could not be solved by optimized compensations. We then 
used all fluorescent-conjugates together to establish optimal compensation and develop an 
efficient gating strategy (Figure 2.3). 
Samples selected for flowFISH assays were stained, post-stimulation, as per 
section 3.1. and re-suspended in 1% FCS-PBS, rather than 1% PFA, after intracellular 
staining. 
  
	   	  




Figure 2.2. Flow cytometry events of gated subgroups showing preservation of 
antibody-conjugated fluorochromes during the flowFISH process. 
 (a) Identification of a positive fluorescent signal, post-hybridization. (b) Addition of 
the Cy3 probe to flowFISH hybridization indicates no large spectral overlap or 
compensation issues that would inhibit clear signal of either fluorochromes or Cy3-
Tel C probe. TelC-Cy3, Telomere C-rich peptide-nucleic acid cyanine-3 conjugated 
probe; QD705, Quantum Dot 705; FITC, fluorescein isothiocyanate; APC, 
allophycocyanin, IFN- interferon. 	  
	   	  




Figure 2.3.  Gating strategy of representative flow cytometry events to 
determine telomere length of CMV-specific CD57+CD8+ T cell subsets. 
PBMC samples were stimulated with overlapping peptides and subjected to 
flowFISH assay to quantify telomere length of different lymphocyte subsets. 
TelC-Cy3, Telomere C-rich peptide-nucleic acid cyanine-3 conjugated probe; 
QD705, Quantum Dot 705; FITC, fluorescein isothiocyanate; APC, 
allophycocyanin, IFN- interferon, CMV, cytomegalovirus.  
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2.6.2 Crosslinking 
	  
To increase stability of antigen-antibody-conjugate complexes, 200 µL of a 7.5 
mM BS3 (Thermofisher Scientific, Massachusetts, USA)-PBS crosslinking solution was 
added to PBMC to a final concentration of 5 mM. PBMC were incubated in cross-linker 
on ice for 30 minutes. Residual BS3 was quenched with 3 mL quenching solution (100 
mM Tris-HCl, 50 mM NaCl in PBS). Samples were left to incubate on ice for a further 20 
min. At this point, 1301 cells were added at a ratio of 1:4 to sample PBMC 
(approximately 0.5 x 106 cells). Samples were then washed in flow buffer, split into two 
aliquots of approximately 1.25 x 106 cells and added to clean 1.5 mL microcentrifuge 
tubes. 
2.6.3 Hybridization 
Samples were pelleted and all but 100 µL of the supernatant was removed via 
pipette to ensure pellet stability. To ensure maximal accuracy of signals and sample 
concentrations, 250 µL of pre-hybridization solution (70% formamide, 30 mM Tris HCl, 
0.2 M NaCl, 1.5 % bovine serum albumin (BSA)) was added. Samples were then 
resuspended via wide bore 1000 µL pipetting and left to incubate for 10 min at RT. All 
subsequent resuspensions were done in this manner to avoid unnecessary shear force on 
fragile samples. Samples were then centrifuged at 1600g to ensure optimal pellet 
formation in formamide without compromising cellular integrity. All but 100 µL of 
supernatant was removed via pipette. Samples were then resuspended in 250 µl 
hybridization solution (70% formamide, 30 mM Tris HCl, 0.2 M NaCl, 1.5 % BSA) with 
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or without the addition of 0.75 µg/ml TelC-Cy3 (Panagene). An unprobed sample (FMO) 
to allow for proper correction for formamide-related auto-fluorescence that may 
artificially increase measured Cy3 fluorescence, was run with every experiment. All 
aqueous reagents were verified pH 7.2, followed by sterile filtration through a 0.45 µm 
nylon filter prior to formamide addition. 
Samples were then incubated at 84°C for 10 minutes and immediately placed on 
ice for 5 minutes. Samples were left to hybridize in a dark chamber for 2 hours at RT. 
Samples were then diluted 3:1 with a post-hybridization solution (70% formamide, 15 
mM Tris HCl, 0.2 M NaCl, 0.15% BSA, 0.15% Tween-20) and centrifuged at 1600g.  
Samples were pelleted and all but 100 µl of supernatant was removed via pipette. 
Samples were then washed twice with another wash solution (1.0% BSA, 0.5 mM EDTA, 
in PBS), and centrifuged twice, first at 900g and then at 500g, to account for varying 
concentrations of formamide. These washing steps ensure maximal removal of 
formamide that may damage the fluidic properties of the flow cytometer or cross-react 
with sanitizing bleach. Samples are re-suspended in the same wash solution and then 
analyzed immediately with a FACS Calibur Cell Analyzer (BD Biosciences). A minimum 
of 1 x 105 events were acquired per sample. 
2.3.4 Calculation of Relative and Exact Telomere Length  
Using the Cy3 MFI of the 1301 control cell line and sample(s), the relative 
telomere length of the subset is calculated and using the known 1301 telomere length, the 
exact telomere length (bp) of the subset is calculated.  
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2.7 Enzyme-linked Immunosorbent Assays (ELISA) for Serum Protein 
Quantification 
Fresh plasma was aliquoted to smaller portions to avoid repeated freeze/thaw 
cycles. Previous exposure to CMV was confirmed by an in-house CMV lysate-ELISA 
described in Heath et al.132 IL-1β (eBioscience, range = 2.00 – 200.00 pg/ml), IL-6 
(eBioscience, 2.00 – 200.00 pg/ml), TNF-α (eBioscience, 4.00 – 500.00 pg/ml), 
fractalkine (R&D, Minneapolis, MN, USA, 0.63 – 20.00 ng/mL), C-reactive protein 
(R&D, 15.60 – 1,000.00 pg/mL) were quantified according to manufacturer’s protocol. 
All ELISA sensitivity ranges covered physiologically appropriate levels such that plasma 
was added neat to the assay, except for CRP where plasma was diluted 1:10,000 with 
PBS.  All samples were measured in duplicate, and each ELISA contained a control well 
with only sample diluent added. This value was then subtracted from all values to adjust 
for background. Absorbance was measured at 450 nm on a Biotek synergy HT ELISA 
reader (Gen5). 
2.8 Statistical Analysis 
Statistical analyses were carried out using Prism version 6 (GraphPad Software, 
Inc., La Jolla, CA, USA). Normal distribution of data was assessed by the Shapiro–Wilk 
	   	  
	   53 
test. If any test indicated deviation from normal distribution (all TL results, IL-1β, IL-6, 
TNF-α, fractalkine), data were represented with median ± interquartile range (IQR) and 
group medians compared by Mann–Whitney test or Wilcoxon signed rank test. Spearman 
correlation was used to assess relationships between variables. If data were normally 
distributed (age, CRP, CMV CD8 T cell response), mean ± SD was calculated and 
Student's t-test was used to compare means. Relationships were assessed using Pearson 
correlation matrices. 
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3 Results 
  3.1 Study Groups and Clinical Characteristics 
To assess the prevalence of chronic inflammation in association with CMV 
infection, we measured IL-1β, IL-6, TNF-α, fractalkine and CRP in 116 HIV-infected 
individuals, 19 seronegative for HCMV and the remaining 97 HCMV-seropositive. 
Subjects selected for these analyses were on antiretroviral therapy (ART), possessed pro-
calcitonin levels below 0.1 ng/ml (results not shown) and were of similar age range in 
each group. Responses to overlapping CMV peptides were significantly different between 
groups, complementing previously assayed CMV-seropositivity126. No significant 
differences were observed in duration of ART or CD4+ nadir. These comparisons and 
other relevant demographic information, such as: age; CD4+/CD8+ differential counts; β2 
microglobulin; are presented in Table 3.1. Subjects with detectable antibodies against 
hepatitis C virus (HCV) or who had undergone any type of chemotherapy were not 
included in the study. 
3.2 Measurement of inflammatory cytokines, chemokines and acute phase 
protein C-reactive protein in plasma 
Of the plasma components studied, median levels (+ IQR) of inflammatory 
cytokines that were significantly higher in the group co-infected with CMV in 
comparison to the CMV-uninfected group were IL-1β (6.04 [2.00-14.98] pg/mL vs 2.00 
[2.00-7.15] pg/mL, p = 0.044), IL-6 (4.12 [2.00-12.06] pg/mL vs 2.22 [2.00-2.45] pg/mL, 
p = 0.0037) and TNF-α (11.39 [4.00-57.84] pg/mL vs 4.00 [4.00-9.89] pg/mL, p = 
0.0185). The acute phase protein, CRP was also elevated in the group co-infected with 
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CMV (3.436[1.763-6.830] µg/mL vs 1.659 [0.659-4.193] µg/mL, p = 0.0385). There was 
no significant difference in levels of the chemokine fractalkine (CX3CL1) between 
groups. These data, outlined in Table 3.2 and Figure 3.1, demonstrate that multiple 
markers of systemic inflammation are significantly higher in the group of HIV-infected 
individuals co-infected with CMV.  While there is considerable overlap in levels of these 
markers between groups, median levels are significantly higher with CMV co-infection.  
To determine if HIV replication had any impact on the levels of these markers of 
inflammation, results for 25 individuals with detectable HIV viral load (log10  HIV RNA 
copies/mL plasma >1.3) were removed and data were then reanalyzed (Table 3.2 and 
Figure 3.1b). With this adjustment, upon comparison of the HIV-infected group co-
infected with CMV to the uninfected group, the difference in median levels of IL-1β 
became insignificant, while differences in median levels of IL-6 (5.63 [2.00-13.74] pg/mL 
vs 2.23 [2.00-3.51] pg/mL, p = 0.0074), TNF-α (14.41[4.00-62.29] pg/mL vs 4.00 [4.00-19.83] 
pg/mL, p = 0.0456) and CRP (3.936 [1.862-7.210] µg/mL vs 1.932 [0.841-4.105] µg/mL, 
p = 0.0205) remained significant. Interestingly, despite the HIV-infected group co-
infected with CMV having high plasma concentrations of inflammatory biomarkers, these 
levels did not correlate with frequency of CMV-specific CD8+ T cells (data not shown). 
This indicates that the increased levels of IL-6, TNF-α, and CRP observed with CMV co-
infection in HIV-infected subjects are independent of any effect due to HIV replication. 
  
	   	  




Table 3.1 General characteristics of CMV-seropositive and seronegative HIV-infected 
individuals. 
General Characteristics  CMV- CMV+ p 
n (% undetectable #) 19  (84%) 97 (77%) 0.5459 ns 
Age (years), Median (IQR) 44 (42-50) 48 (44-54) 0.1165 ns 
B2M (µg/mL), Median (IQR) 2.63 (2.06-3.24) 2.64 (2.08-3.33) 0.9082 ns 
% CMV Specific CD8+ T cells, Mean (+/- SD) 0.01 0.03 3.94 4.15 <0.0001 *** 
CD4+ T cell Count (cells/µL), Median (IQR) 742 (522-780) 648 (419-777) 0.7689 ns 
CD8+ T cell Count (cell/µL), Median (IQR) 648 (442-770) 869 (643-1217) 0.0093 ** 
CD4+:CD8+ T cell Ratio, Median (IQR) 1.05 (0.86-1.64) 0.68 (0.44-0.92) 0.1273 ns 
Duration of ART (years), median (IQR) 13 (8-19) 15 (10-19) 0.3753 ns 
Nadir CD4+
 
T cells/µL blood, median (IQR) 190 (89-325) 234 (121-404) 0.3655 ns 
 
Patients chosen for experiments involving inflammatory biomarker and telomere 
length quantification. # Undetectable < 1.3 log10 HIV RNA copies/mL plasma. Two-
tailed Student’s unpaired t test. B2M, beta-2-microglobulin; CMV, cytomegalovirus. 
	   	  





Table 3.2 Inflammatory Biomarker Comparison 
Inflammatory Biomarker 
CMV-  CMV+ 
p 
Median  IQR Median  IQR 
IL-1β (pg/mL) 2 (2.00-7.15) 6.04 (2.00-14.98) 0.044 * 
IL-6 (pg/mL) 2.22 (2.00-2.45) 4.12 (2.00-12.06) 0.0037 ** 
TNF-α (pg/mL) 4 (4.00-9.89) 11.39 (4.00-57.84) 0.0185 * 
Fractalkine (CX3CL1) (ng/mL) 0.74 (0.533-0.970) 0.881 (0.590-1.187) 0.1781 ns 
C-reactive Protein (CRP) (µg/mL) 1.659 (0.645-4.193) 3.436 (1.763-6.830) 0.0385 * 
IL- 1β* (pg/mL) 2.14 (2.00-7.62) 5.64 (2.00-14.09) 0.1795 ns 
IL- 6 * (pg/mL) 2.23 (2.00-3.51) 5.63 (2.00-13.74) 0.0074 ** 
TNF-α* (pg/mL) 4 (4.00-19.83) 14.41 (4.00-62.29) 0.0456 * 
Fractalkine* (CX3CL1) (ng/mL) 0.789 (0.568-0.972) 0.919 (0.575-1.210) 0.2131 ns 
C-reactive Protein (CRP)* (µg/mL) 1.932 (0.841-4.105) 3.936 (1.862-7.210) 0.0205 * 
 
Inflammatory biomarker comparison between HIV-infected CMV-seropositive (n=97) 
and HIV-infected CMV-seronegative (n=19) study groups. Values were determined by 
ELISA, as per manufacturer’s instructions (see Methods) and medians compared by 
two-tailed Mann-Whitney U Test. IL, interleukin; TNF, tumor necrosis factor; CMV, 
cytomegalovirus. * Only individuals with undetectable HIV viral load were considered 
(CMV-, n = 16; CMV+, n = 75). 
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Figure 3.1. Inflammatory Biomarker Comparison of HIV+CMV-seropositive and 
HIV+CMV-seronegative individuals. 
 (a) Represents all individuals chosen for assessment (CMV-, n = 19; CMV+, n = 97). 
(b) Comparisons and analyses were performed again, with all individuals with a 
detectable HIV viral load excluded (> 1.3 log copies/µL) (CMV-, n = 16; CMV+, n = 
75). Values were determined by ELISA as per manufacturer’s instructions (see 
Methods 2.7). Median and interquartile range are represented with horizontal bars and 
medians compared by two-tailed Mann-Whitney U Test. IL, interleukin; TNF, tumor 
necrosis factor; CMV, cytomegalovirus. 
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3.3 Telomere Length (TL) of T Lymphocyte Subsets 
Applying the gating strategy shown in Figure 2.3 allowed us to acquire TL 
information from 6 defined subsets of lymphocytes from 32 CMV co-infected individuals 
infected with HIV. These sequentially more discrete subsets include global lymphocytes, 
CD8+ T lymphocytes, CD57+ and CD57- CD8+ T lymphocytes. Within the CD8+ and 
CD57+ CD8+ T lymphocytes CMV- and HIV-specific T lymphocytes were identified by 
IFN-γ production following PBMC stimulation with CMV or HIV peptides. Absolute TL 
values were obtained as outlined in the methods using the acquired Cy3 MFI and known 
TL of the 1301 control cell line. As this assay is not yet optimized for high-throughput 
format, 34 individuals tested is assumed representative. Paired comparisons of subset 
TLs, showed that the median lymphocyte telomere length (3133 bp, LTL) was the longest 
with a significant difference from that of CD8+ T lymphocytes (p <0.0001, Figure 3.2a). 
The median telomere length of CD8+ T lymphocytes (2782 bp) and CD57-CD8+ T 
lymphocytes (3088 bp) was significantly greater than that of the CD57+CD8+ T 
lymphocytes (2594 bp, p <0.0001, 0.0001, respectively, Figure 3.3a, 3.2b), corroborating 
a wealth of literature indicating CD57 expression is a marker of long term, extensive T-
cell replication. The main aim of the assay was to determine the TL of the CMV-specific 
CD57+CD8+ T lymphocytes, and compare it to LTL, CD8+ TL, and the reciprocal CD57+ 
CD8+ T cell population. In comparison to these identified subsets, the CMV-specific 
CD57+CD8+ T cell compartment showed the lowest median TL (2122 bp, p <0.0001, 
0.0001, 0.0001, respectively, Figure 3.2c, 3.3b, c). This demonstrates that CMV-specific 
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T lymphocytes residing in the highly proliferated CD57+ CD8+ T cell population are the 
CD8+ T lymphocyte subset most proximal to telomere-dependent replicative senescence. 
The genetic predisposition, age and environmental exposures of each HIV-
infected individual with CMV co-infection contribute to the heterogeneity of telomere 
lengths within the T lymphocyte subsets presented in figures 3.2 and 3.3. Therefore, in 
figure 3.4 the ratio(s) of CD8+ (0.9364 bp/bp), CD57+CD8+ (0.8938 bp/bp), and CMV-
specific T lymphocytes (0.7944 bp/bp) to global lymphocyte TL are presented for each 
individual tested. These ratios demonstrate the increased telomere erosion exhibited 
within these CD8+ T subsets compared to global lymphocytes, thereby masking 
individual differences. 
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Figure 3.2. Telomere length of targeted lymphocyte populations 
(a) CD8+ T cells possess a shorter average telomere length than the general 
lymphocyte population. (b) CD57+CD8+ T cells possess a shorter average telomere 
length than the CD57-CD8+ T cell population. (c) CD57+CD8+ T cells not directed 
against CMV-peptides possess a longer median telomere length than those that 
produce IFN-γ when stimulated with CMV-peptides. All PBMC samples were 
stimulated with overlapping peptides and subjected to flowFISH assay to quantify 
telomere length (See Methods 2.6). Data is collected from 32 HIV-infected CMV-
seropositive individuals and compared using Wilcoxon signed rank test. TL, telomere 
length; IFN, interferon; CMV, cytomegalovirus.  
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Figure 3.3. Telomere length of CD8+ T cell subsets distinguished by functional 
markers 
(a) CD57+CD8+ T cells, defined by the terminal differentiation marker CD57, possess 
a shorter average telomere length than the general CD8+ population. (b, c) Both 
general CD8+ and general CD57+CD8+ T cells possess a longer average telomere 
length than those that produce IFN-γ when stimulated with CMV-peptides, a 
population with a potentially senescent phenotype. All PBMC samples were stimulated 
with overlapping peptides and subjected to flowFISH assay to quantify telomere length 
(See Methods 2.6). Data is collected from 32 HIV-infected CMV-seropositive 
individuals and compared by Wilcoxon signed rank test. TL, telomere length; IFN, 
interferon; CMV, cytomegalovirus. 
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Figure 3.4. Average telomere length of selected subsets expressed as a fraction of 
total lymphocyte population average telomere length. 
Median and interquartile range are represented with horizontal bars. Data were 
collected from 32 HIV-infected CMV-seropositive individuals. TL were determined 
by flowFISH (see Methods 2.7).   (Although data is not graphically shown as paired 
tests, transformed data analyses were performed just as with the untransformed data 
using Wilcoxon signed rank test). TL, telomere length; LTL, lymphocyte telomere 
length; CMV, cytomegalovirus. 
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 3.4 Correlation between CMV-specific CD57+CD8+ T cell TL and Frequency of 
CMV-specific CD8+ Responses 
It should be noted that absolute CD8+ T cell counts are significantly higher in the 
HIV infected group co-infected with CMV (869 cells/µL vs 648 cells/µL, p = 0.0093, 
Table 3.1), a feature reflecting an underlying elevation of CD8+ T cell clonal 
proliferation.  To follow up the observation of highly eroded TL of clonally expanded, 
CMV-specific T lymphocytes, we investigated if there was an association between the 
degree of telomere erosion in CMV-specific CD57+CD8+ T cells and the magnitude of 
CMV-specific CD8+ T cell responses in each individual. We chose to compare the ratios 
of CMV-specific CD57+ CD8+ T cell to LTL in order to minimize inter-individual age-
related variations. Figure 3.5 illustrates a co-ordinate increase in CMV-specific CD8+ T 
cell-mediated responses and decreases in normalized CMV-specific CD57+ CD8+ T cell 
TL, however, this relationship was not statistically significant (p = 0.0858, r = -0.3036 ).  
  
	   	  




Figure 3.5. Median TL of CMV-specific CD57+CD8+ T cells versus magnitude of 
the anti-CMV response residing in this subset. 
CMV-specific responses were determined as per Methods 2.6.  TL was determined as 
per flowFISH in Methods 2.7. Data were collected from 32 HIV-infected CMV-
seropositive individuals. Pearson Correlation with TL ratio(s). TL, telomere length; 
LTL, lymphocyte telomere length; CMV, cytomegalovirus. 
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3.5 Comparison of CMV-specific and HIV-specific CD8+ T Cell TL  
To test whether the dramatic TL erosion observed within the CMV antigen-
specific CD57+CD8+ T cells was selective for the CMV response and not just an intrinsic 
quality of all antigen-expanded memory T cells, we compared the TL of another antigen-
specific CD8+ T cell population. We chose HIV-specific CD8+ T cells for comparison as 
this population was large enough for similar analysis. However, it should be noted this 
comparison could only be made within CD8+ T cells, since too few HIV-specific CD8+ T 
cells expressed the terminal differentiation marker, CD57. Figure 3.6 shows the 
differences in the ratios to overall LTL of HIV-specific CD8+ and CMV-specific CD8+ T 
cell TL for 6 HIV-infected individuals co-infected with CMV (0.9218 vs 0.8013, p = 
0.0461). These data show that HIV-specific CD8+ T cells possess similar TL to general 
CD8+ T lymphocytes and overall lymphocytes and retain longer TL than CMV-specific 
CD8+ T cells. Thus, the degree of telomere erosion present in the CMV-specific CD8+ T 
cell compartment surpasses that seen in CD8+ T cells specific for other chronic viral 
pathogens.  
  
	   	  




Figure 3.6. Comparison of average telomere length of HIV- and CMV-specific 
CD8+ T cell subsets.  
HIV-specific and CMV-specific telomere lengths were measured in 6 individuals with 
detectable anti-HIV responses using flowFISH (as per Methods 2.7). Wilcoxon signed 
rank test. TL, telomere length; LTL, lymphocyte telomere length; HIV, human 
immunodeficiency virus, CMV, cytomegalovirus. 
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3.6 Correlation between CMV-specific CD57+CD8+ T cell TL and Age 
A general assumption of TL is that it decreases with biological age. In agreement with 
this assumption, we found a strong significant correlation between the TL of lymphocytes 
and biological age of the donor (p = 0.0042). How the TL of CMV-specific CD57+ CD8+ 
T lymphocytes TL varies with age has not yet been studied in the context of HIV 
infection. Data presented in Figure 3.7, show that CMV-specific CD57+CD8+ T cell TL 
does decline with age, however, only to a slightly lesser extent than total lymphocytes (p 
= 0.0098). In addition, when presented as a ratio of lymphocyte TL (Figure 3.8), there is 
no difference with respect to age. These data show that age has an impact on the decline 
in TL within the CMV-specific compartment, but that other factors extrinsic to 
chronology overwhelm the effect of aging.  
  
	   	  




Figure 3.7. The average telomere length of general lymphocytes and the CMV-
specific CD57+CD8+ T cell population are associated with biological age. 
Data were collected from 32 HIV-infected CMV-seropositive individuals. TL are 
determined by flowFISH (see Methods 2.7).  Pearson correlation with age. TL, telomere 
length; CMV, cytomegalovirus. 
	   	  




Figure 3.8. Ratio of telomere length of general lymphocytes and the CMV-specific 
CD57+CD8+ T cell population versus age. 
 Data were collected from 32 HIV+ CMV-seropositive individuals. TL are determined 
by flowFISH (see Methods 2.7).  Pearson correlation with TL ratio(s). TL, telomere 
length; LTL, lymphocyte telomere length; CMV, cytomegalovirus. 
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3.7 Correlation between plasma markers of inflammation and CMV-specific 
CD57+ CD8+ T cell TL 
 To investigate a potential relationship between elevation of plasma markers of 
inflammation, and TL of CD8+ T lymphocytes, particularly of CMV-specific CD57+ 
CD8+ T cells, we assessed correlation between levels of these parameters. The levels of 
IL-1β, IL-6, TNF-α, and fractalkine were not significantly correlated with any 
lymphocyte subset TL or frequency of CMV-specific CD8+ T cells, however, CRP levels 
were significantly correlated with CMV-specific CD57+CD8+ TL (p = 0.0122, Figure 
3.9). CRP also showed a significant direct correlation with age (p = 0.0291, Figure 3.10). 
  
	   	  






Figure 3.9.   Relationship between CD57+CD8+ CMV-specific T cell: Lymphocyte 
telomere lengths and C-reactive protein levels in plasma. 
Data were collected from 32 HIV+ CMV-seropositive individuals. CRP values are 
determined by ELISA as per manufacturer’s instructions. TL are determined by 
flowFISH (see Methods 2.7).  Pearson correlation with TL ratio(s). TL, telomere 
length; LTL, lymphocyte telomere length; CMV, cytomegalovirus. 
	   	  




Figure 3.10. Relationship between biological age and C-reactive protein levels in 
plasma. 
Data is collected from 32 HIV-infected CMV-seropositive individuals. CRP values 
were determined by ELISA as per manufacturer’s instructions. Pearson correlation 
with age. 
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4 Discussion 
	  
In attempts to study mechanisms underlying physiological aging, researchers 
have uncovered that complex factors beyond just chronological age are involved. Like 
most homeostatic and regulatory cellular processes within the body, cellular senescence 
and its eventual culmination in organismal aging are intimately associated with the 
immune system. Short lived, acutely senescent cells arise during beneficial wound 
healing or vascular remodelling and are identified and cleared by immune cells such as T 
and NK cells. Conversely, long lived chronically senescent cells accumulate in high 
numbers in biologically aged tissue due to reduced immune clearance. These senescent 
cells acquire a pathological phenotype characterized by chronic production of 
inflammatory mediators, cell cycle arrest, and resistance to apoptosis.  This chronic 
cellular senescence often develops through exhaustive division, during which eroding 
telomeres reach Hayflick’s limit, triggering cell cycle arrest. Increased DNA damage 
repair pathway activation enforces the observed senescence, which often manifests a pro-
inflammatory cellular phenotype in attempts to communicate internal cellular distress to 
nearby immune cells. While most somatic tissues exhibit homeostatic cellular turnover 
and repair, cells rarely reach this divisional limit and level of telomeric degradation 
before immune cell mediated clearance. However, situations where immune responses are 
insufficient or unavailable could lead to an increase in senescent cell accumulation.  
It is well recognized that the elderly immune system provides less robust 
pathogen clearance, decreased vaccine responsiveness and reduced immunosurveillance 
in comparison to a young or middle aged individual. It is now speculated that these 
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observed clinical features are an illustration of the immune system itself undergoing a 
type of chronic senescence, a point at which age-related immune incompetence 
compounds the high tissue-resident senescent cell accumulation accompanying 
chronological aging.  Much like cells of the peripheral tissue, loss of telomeric DNA in 
white blood cells has been proposed as a mechanism of immune senescence and was first 
associated with poor survival in elderly by Cawthon et al60. The highest observed causes 
of mortality were due to infectious disease and cardiovascular disease complications, with 
the lowest survival rates observed in individuals with the shortest telomere length. 
Cawthon et al. speculated that telomere length within peripheral blood subsets could 
indicate a progressive senescence that alters mortality rates, but such erosion occurred via 
an unknown mechanism and suggested a causal role of aging. Therefore, the aging 
immune system, once typically beneficial during youth in the prevention and amelioration 
of cellular and tissue aging, becomes -much like autoimmune disease- a pathogenic 
contributor to the physiological aging process. Senescent cell accumulation within tissue 
and downstream pathological sequelae such as increased inflammation and extracellular 
matrix destruction are, therefore, directly related to cellular immune senescence.   
Despite the implications of this study, the operative mechanism and the specific 
subsets of immune cells directly involved in increasing mortality remain unidentified, 
although the immune cell senescence associated inflammatory immune phenotype 
(SASP) has recently been suggested as causal. However, the short half-life and high 
turnover of innate immune cells, such as neutrophils, suggest that long lived highly 
proliferated lymphocytes of the adaptive immune system are the leukocytes bearing 
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shorter telomere lengths. The adaptive immune system, including B and T lymphocytes, 
comprises a distributed organ that does not undergo simple cellular turnover and 
homeostasis. Strict selection of T lymphocytes within the thymus gives rise to a restricted 
set of TCR-defined clonal populations. These populations expand when cognate antigen 
is encountered, and only partially contract during antigen clearance to leave memory cells 
that have previously proliferated. TCR-restricted memory cells expand through additional 
rounds of proliferation during subsequent antigen exposures to replenish high numbers of 
specific pathogen-clearing effector T cells when needed. Each series of expansion and 
contraction sacrifices telomere length and presumably positions this specific clonal 
population closer to cellular senescence. Unique opportunities to study in vivo immune 
senescence can arise from the persistent antigenic stimulation that results from chronic 
infections.  
CMV infection persists as a lifelong subclinical infection in healthy individuals, 
however, this typically generates a CMV-specific CD8+ T cell population expanded to a 
unique degree. These large oligoclonal CD8+ T cell expansions are restricted to several 
TCR epitopes and are predominantly of an effector memory phenotype. There is 
speculation that this extensive CMV-specific CD8+ T cell population, which has 
undergone many rounds of proliferation, possesses many classical features of chronic 
senescence such as cell cycle arrest, heightened pro-inflammatory cytokine production, 
and resistance to apoptosis. Despite CMV infection remaining predominantly latent, at 
least from a clinical perspective, this CMV-specific CD8+ T cell population grows with 
age, in parallel with the accumulation of senescent cells within aging tissue. Linking 
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aging with adaptive immunity, Pawelec et al. have shown that increases in B and T cell 
responses directed against CMV are strongly associated with “Immune Risk Profile” 
(IRP) parameters seen during aging56. Features of the IRP such as inversion of the 
CD4+/CD8+ T cell ratio, increased absolute numbers of CD8+ T cells, poor T cell 
responses to mitogens, and interestingly, chronic inflammation, are common to the old 
elderly and to HIV-infected individuals co-infected with CMV.  Thus, there is a 
theoretical and experimental framework positioning telomere attrition within expanded 
CMV-specific CD8+ T cells, and the factors facilitating this expansion, as mechanisms 
contributing to chronic immune senescence, and the subsequent IRP, thereby accelerating 
the physiological aging process.   
While a chronic manageable infection with the advent of HAART, HIV infection 
leaves individuals at heightened risk for early onset of age-associated diseases. Bestilny et 
al. cite a 15-year discrepancy (accelerated erosion) in leukocyte telomere length of HIV-
infected individuals compared to an HIV-uninfected age-matched control group146. CMV-
specific CD8+ T cell populations typically become large in aging individuals, however, 
expansion of this population occurs earlier in life and is exaggerated in HIV-infected 
individuals. In the general population, CMV-specific CD8+ T cell populations increase 
with age with immune cell telomere length decreasing, but these two features of immune 
cell replication have not yet been directly linked in HIV infection. We have previously 
shown that immune features seen in the old elderly (IRP), such as low CD4+/CD8+ T cell 
ratios and increased CD57 expression on CD8+ T cells are exhibited to a greater extent in 
HIV-infected subjects co-infected with CMV compared to CMV-uninfected groups of 
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HIV-infected individuals.127 To address the missing link between the uniquely altered 
immune cell composition seen exclusively in HIV-infected subjects living with CMV and 
the observed premature aging in the same group, we determined that the highly expanded 
CMV-specific CD8+ T cells of HIV-infected individuals possess dramatically reduced 
telomeres in comparison to the larger CD8+ T cell population, even in comparison to 
HIV-specific CD8+ T cells.  These are the first data positioning CMV co-infection as a 
driving factor of lymphocyte telomere erosion, equivalent to that occurring in elderly 
individuals, in HIV infection.  
Previous studies addressing the role of telomere-dependent replicative 
senescence within CMV-specific CD8+ T cells focused on traditional T cell effector 
function and phenotype.81 In most cases, traditional multi-cytokine producing (IL-2, 
TNF-α, IFN-γ) CMV specific (using the public HLA-A2 restricted epitope 
NLVPMVATV) CD8+ T cells did not possess the shortest telomeres. Furthermore, no 
association of enhanced cytokine producing CD8+ T cells with telomere length was 
observed, contrasting the telomere-dependent SASP hypothesis. These studies involved in 
vitro selective expansion of CMV-specific CD8+ T cells (expanded with IL-2 and NLV 
antigen, an HLA-A*02 restricted CMV tetramer), followed by re-stimulation with NLV 
peptide and assays for poly-functionality and telomere length via flowFISH. Conversely, 
we did not utilize IL-2 or MHC-tetramers to expand or identify CMV-specific 
populations. We aimed to limit the modes of activation involved in our procedures, as it is 
known that IL-2 (even via the low-affinity receptor, CD122) can trigger expression of 
telomerase. In order to identify the most representative of in vivo telomere lengths, we 
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chose to identify antigen-specific compartments strictly by IFN-γ production via 
overlapping peptide-stimulation ex vivo of primary PBMC.  In addition, by focusing on 
the NLV epitope, the previously published data was restricted to HLA-A2 donors, while 
we were successful in measuring CMV-specific CD8+ T cell telomere lengths of CMV-
specific T cells specific to the public immunogenic regions of CMV proteins pp65 and 
IE-1 in individuals of diverse HLA types. Therefore, our method allows for a more 
accurate in vivo representation of telomere length dynamics within the CD8+ T cell 
subsets analyzed.  
If and how CMV-specific T cell senescence contributes to the premature 
physiological aging exhibited in treated HIV infection remains unclear, however, several 
studies suggest that gradual increases of senescent, and often pro-inflammatory cells 
within tissue directly links aging to increased levels of chronic inflammation. Our data 
also show that coinfection with CMV is associated with higher plasma levels of 
inflammatory biomarkers in HIV infected individuals, such as TNF-α, IL-1β, IL-6, and 
CRP. Increased systemic CRP, a dominant indicator of risk for cardiovascular disease, is 
particularly prominent in individuals with shorter CMV-specific CD8+ T cell telomere 
length. This correlation corroborates the link described by Pawelec et al., in the general 
population and emphasizes the connection between aging and CMV in the context of HIV 
infection, potentially linked by related repercussions apparent in the immune repertoire147. 
Persisting senescent cells within vasculature can often secrete IL-1β and IL-6 to inflict 
localized inflammation in a paracrine manner, but additionally can systemically trigger 
the acute phase response in an endocrine manner, resulting in CRP production. 
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Alternatively, CMV-infected cells within tissue can recruit highly cytotoxic CMV-
specific CD8+ T cells, which circulate in high numbers in the periphery. Secreted IFN-γ 
and TNF-α from recruited memory CD8+ T cells can also contribute to systemic 
inflammation both directly and by acting on tissue resident innate immune cells, such as 
macrophages, to trigger inflammasome formation and reactive oxygen/nitrogen species 
secretion. Chronic increases in such systemic inflammatory mediators are positioned, 
clinically, as having the strongest predictive values of the onset of age-related 
morbidities. The results of this project provide the first statistical evidence of an 
association between inflammation and immune cell telomere length, a biomarker of 
lymphocyte cellular senescence, in the context of CMV infection. This potentially bridges 
the gap between extensive CMV-specific T cell expansion and increases in inflammation, 
highlighting a mechanistic role for CMV co-infection in premature aging of HIV-infected 
individuals. 
Despite identifying links between chronic inflammation, lymphocyte telomere 
length and the CMV immune response, we have not shown any direct role in the 
aforementioned inflammation for CMV-specific CD8+ T cells. The poorly described 
senescent CD8+ T cell phenotype, in the context of both surface marker expression and 
effector function, is a large obstacle to definitive research in this area. It remains 
unknown if traditional markers of T cell effector function (ie. IFN-γ and TNF-α) are 
useful to identify a potential SASP-like activity pattern, or if single-cell transcriptional 
profiling is required to discover the unique reprogramming of senescent CD8+ T cells. It 
has been recently described by Akbar et al. that CD45RA+ effector memory CD8+ T cells 
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express a secretory phenotype largely dominated by proteases more so than inflammatory 
cytokines/chemokines, much like the granzyme (serine proteases) secretory profile of NK 
cells.141 Furthermore, as T cells reach stages of terminal differentiation, surface 
expression of NK-associated receptors is notably increased.  However, it remains 
unknown whether this is indicative of any NK-associated behavior. In addition to the 
previously mentioned CD57 and CD16, other NK markers such as: killer-cell 
immunoglobulin-like receptors (KIR), killer-cell lectin-like receptors (KLR) and CD85j 
(LIR), are also expressed on CMV-specific T cells.69,70,72 Understanding the parameters 
which not only CMV-specific, but global T cell senescence alters, translates, or augments 
to impact on classical T effector functions is crucial for addressing lymphocyte 
senescence.  
Our results affirm involvement of the adaptive immune system in biological 
aging and further substantiate chronic viral infections as accelerators of immune 
senescence. A prominent feature of aging is reduced immune mediated cell clearance and 
subsequent accumulation of senescent cells within the peripheral tissue, suspected to 
reflect degenerating immune function. Reduced ratios of CD4:CD8 T cells often 
represents a negative restructuring within the immune system that occurs with aging, 
characterized mostly by polyclonal expansion of CD8+ T cells, or a large decrease in 
CD4+ T cells (i.e. HIV infection). Large oligoclonal populations of CD8+ T cells can 
negatively affect the reciprocal CD8+ T cell population via metabolite deficiency or 
“space competition.” Populations affected by such inhibition could represent the CD8+ T 
cell subsets responsible for senescent cell clearance from peripheral tissue. Highly 
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differentiated CD8+ T cells, like the effector memory CD8+ T cells specific to CMV-
antigens, often possess regulatory functions and can suppress CD8+ T cells of different 
specificity via Fas:FasL engagement and other fratricidal, autocrine or paracrine cell 
interactions leading to upregulation of exhaustion markers such as programmed cell death 
1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4) and T cell immunoglobulin and 
mucin domain 3 (TIM3)87. Interestingly CD57 expression on the overall CD8+ T cell 
population is increased during both CMV infection and HIV infection, indicating that 
increases in inflammation, including immune activating molecules such as IFN-γ, 
contribute to increases in homeostatic CD8+ proliferation in addition to the extensive 
replication seen in the potentially replicative-senescent CD8+ T cells directed against 
CMV. Enhancing replication of CD8+ T cells, without TCR-engagement, could drive 
nearby CD8+ T cells, and other lymphocytes, closer to replicative senescence. Inhibition 
of, and premature imposition of exhaustion on proximal CD8+ T cells by CMV-specific T 
cells could compound the problem through decreased clearance of senescent cells from 
peripheral tissue, therefore it is of paramount importance to identify how CMV-specific 
CD8+ T cells interact in vivo.   
Dominant suppressive effects on the overall CD8+ T cell population due to 
highly expanded CMV-specific memory CD8+ T cells could also explain reduced 
immune memory development and vaccine effectiveness within the elderly and ART-
suppressed HIV-infected population. Despite poor development of vaccine-induced 
immunological memory in elderly, CMV-specific CD8+ T cells remain highly cytotoxic 
and are functionally maintained throughout life, even in old age. Similarly, maintenance 
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of CMV-specific CD8+ T cells remains undisturbed during HIV infection, despite 
dysfunction observed in most other immune subsets due to lack of CD4+ T helper cell 
function and other factors. 
 The durable immune response developed during HCMV infection prompted 
Hansen et al. to develop a recombinant rhesus (Rh) CMV vector capable of expressing 
gag protein epitopes from simian immunodeficiency virus (SIV)148. Prophylactic 
administration of the RhCMV-SIV led to 50% protection in SIV-exposed macaques, and 
was the first recombinant vaccine shown to elicit protective responses predominantly 
composed of highly cytotoxic effector memory CD8+ T cells.  Much like HCMV-specific 
CD8+ T cells, these SIV-specific CD8+ Tem cells were found in high frequencies in the 
circulation and in the tissue, capable of immediate pathogen identification that allowed 
stringent viral clearance. The shared phenotype observed in the protective CD8+ T 
responses during RhCMV-SIV vaccination and CMV infection may provide long lasting 
and efficacious immunity towards viral epitopes, but likely retain the capacity, like the 
CMV-specific CD8+ T cells identified in our results, to accelerate immune senescence in 
vaccinated subjects. Therefore, identifying how this CMV-specific development and 
maintenance of effector memory CD8+ T cells occurs in natural CMV infection and in 
current recombinant CMV vaccines is crucial to generate future vaccines with not only 
sustainable and efficacious protective immunity but no considerable long term effects on 
aging.  
 Many other chronic virus infections such as HIV infection, can establish latency 
in humans and then reactivate periodically or chronically, but none reinforce such a 
	   	  
	   84 
dramatic CD8+ T cell response or concomitant increase in inflammation as does CMV 
infection.  CMV infections elicit high frequencies of terminally differentiated virus-
specific T cells that can possibly minimize anti-senescent and homeostatic T cell 
responses. Senescent cells accumulate within the blood and tissue during aging and 
contribute to the development of age-associated disease, often by the acquisition of a pro-
inflammatory phenotype. We have presented evidence that CMV-specific, and not HIV-
specific, CD8+ T cells are driven to critical telomere lengths in HIV-infected individuals 
and could illustrate excessive replication as a driving mechanism of lymphocyte 
senescence. Additionally, we show that CMV-infection is associated with increased levels 
of multiple biomarkers of inflammation, particularly CRP, during HIV infection, and 
speculate that this is observable due to increased senescence of the immune system. The 
association between CRP levels and CMV-specific CD8+ T cell telomere erosion could 
introduce new directions for investigating the intimate link between CMV infection and 
enhanced risk of cardiovascular disease seen in HIV-infected and uninfected aging 
populations. Our results reinforce certain immune and inflammatory parameters, such as 
CD8+ T cell telomere length and CRP, as biomarkers of senescence that should be 
considered during recombinant CMV vector vaccine trials as risk factors for CMV 
vaccine-related repercussions on aging, inflammation and immunity. There is still much 
unknown about how CMV can evade and influence the human immune system, however, 
given the high incidence of CMV infection in the global population, understanding how 
CMV infection can alter, or clearly accelerate, the aging process is key in addressing 
rapidly increasing rates of age-associated disease. 
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